[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5732
1. Misago N, Sada A, Narisawa Y: Trichoblastoma with a dilated pore. J Am Acad Dermatol; 2006 Feb;54(2):357-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Scalp. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443076.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


2. Baker SH, Roy M, Thornton SC, Qureshi M, Binns C: Probing atomic structure in magnetic core/shell nanoparticles using synchrotron radiation. J Phys Condens Matter; 2010 Sep 29;22(38):385301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For Fe/Cu nanoparticles, a Cu shell ∼ 20 monolayers thick appears similar in structure to bulk Cu and is sufficient to cause the structure in the Fe core to switch from body centred cubic (bcc; as in bulk Fe) to face centred cubic.
  • This is not the case for thinner Cu shells, 1-2 monolayers in thickness, in which there is a considerable contraction in nearest-neighbour interatomic distance as the shell structure changes to bcc.
  • In Fe/Au nanoparticles, the crystal structure in the Fe core remains bcc for all Au thicknesses although there is some stretching of the lattice.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21386550.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7440-57-5 / Gold; 789U1901C5 / Copper; E1UOL152H7 / Iron
  •  go-up   go-down


3. Limtong S, Kaewwichian R, Am-In S, Boonmak C, Jindamorakot S, Yongmanitchai W, Srisuk N, Kawasaki H, Nakase T: Three anamorphic yeast species Candida sanitii sp. nov., Candida sekii sp. nov. and Candida suwanaritii, three novel yeasts in the Saturnispora clade isolated in Thailand. FEMS Yeast Res; 2010 Feb;10(1):114-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The type strain is RV152(T) (BCC 25967(T)=NBRC 103864(T)=CBS 10864(T)).
  • The type strain is EA1(T) (BCC 29900(T)=NBRC 104877(T)=CBS 11021(T)).
  • The type strain is ST84(T) (BCC 8320(T)=NBRC 105671(T)=CBS 10931(T)).

  • SILVA. SILVA LSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19765089.001).
  • [ISSN] 1567-1364
  • [Journal-full-title] FEMS yeast research
  • [ISO-abbreviation] FEMS Yeast Res.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB332397/ AB332399/ AB332401/ AB332402/ AB332403/ AB439256/ AB495287/ AB495288/ DQ404448
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / DNA, Ribosomal Spacer
  •  go-up   go-down


Advertisement
4. Ahmed N, Salman M, Mansoor MA: Gorlin-goltz syndrome. J Coll Physicians Surg Pak; 2007 Sep;17(9):568-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple jaw cysts are a characteristic manifestation of basal cell nevus (Gorlin) syndrome.
  • Gorlin-Goltz syndrome is characterized by symptoms primarily involving the skin, central nervous system, and skeletal system.
  • In 90% of the patients, nevoid basal cell carcinoma syndrome is associated with recurring odontogenic keratocysts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903410.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


5. Shome D, Bell D, Esmaeli B: Eyelid carcinoma in patients with systemic lymphoma. J Ophthalmic Vis Res; 2010 Jan;5(1):38-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid carcinoma in patients with systemic lymphoma.
  • PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid carcinoma.
  • METHODS: In this non-comparative interventional case series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.
  • Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma.
  • The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases.
  • Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy.
  • Three subjects had high-grade carcinomas.
  • CONCLUSIONS: Systemic lymphoma may be associated with aggressive eyelid carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9 [19033839.001]
  • [Cites] Am J Ophthalmol. 1986 Apr 15;101(4):480-2 [3515953.001]
  • [Cites] Arch Ophthalmol. 1980 Oct;98(10):1771-2 [7000053.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Acta Haematol. 1997;98(1):44-6 [9210914.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Dermatology. 2001;202(4):359-61 [11455161.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Curr Treat Options Oncol. 2004 Jun;5(3):215-23 [15115650.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]
  • [Cites] Histopathology. 2004 Aug;45(2):162-70 [15279635.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):985-8 [15313816.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):49-54 [15621780.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1051-5 [16019557.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):300-4 [16282752.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):231-6 [17034463.001]
  • (PMID = 22737325.001).
  • [ISSN] 2008-2010
  • [Journal-full-title] Journal of ophthalmic & vision research
  • [ISO-abbreviation] J Ophthalmic Vis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3380669
  • [Keywords] NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma
  •  go-up   go-down


6. Madey TE, Chen W, Wang H, Kaghazchi P, Jacob T: Nanoscale surface chemistry over faceted substrates: structure, reactivity and nanotemplates. Chem Soc Rev; 2008 Oct;37(10):2310-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Planar metal surfaces that are rough on the atomic scale, such as bcc W(111), fcc Ir(210) and hcp Re(1231), are morphologically unstable when covered by monolayer films of oxygen, or by certain other gases or metals, becoming "nanotextured" when heated to temperatures above approximately 700 K.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818829.001).
  • [ISSN] 0306-0012
  • [Journal-full-title] Chemical Society reviews
  • [ISO-abbreviation] Chem Soc Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Wu X, Nguyen BC, Dziunycz P, Chang S, Brooks Y, Lefort K, Hofbauer GF, Dotto GP: Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature; 2010 May 20;465(7296):368-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposing roles for calcineurin and ATF3 in squamous skin cancer.
  • Squamous cell carcinoma (SCC) of the skin is a major complication of treatment with these drugs, with a 65 to 100-fold higher risk than in the normal population.
  • By contrast, the incidence of basal cell carcinoma (BCC), the other major keratinocyte-derived tumour of the skin, of melanoma and of internal malignancies increases to a significantly lesser extent.
  • Here we report that genetic and pharmacological suppression of calcineurin/nuclear factor of activated T cells (NFAT) function promotes tumour formation in mouse skin and in xenografts, in immune compromised mice, of H-ras(V12) (also known as Hras1)-expressing primary human keratinocytes or keratinocyte-derived SCC cells.
  • Calcineurin/NFAT inhibition counteracts p53 (also known as TRP53)-dependent cancer cell senescence, thereby increasing tumorigenic potential.
  • Thus, intact calcineurin/NFAT signalling is critically required for p53 and senescence-associated mechanisms that protect against skin squamous cancer development.


8. Brown SJ, Lawrence CM: The management of skin malignancy: to what extent should we rely on clinical diagnosis? Br J Dermatol; 2006 Jul;155(1):100-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of skin malignancy: to what extent should we rely on clinical diagnosis?
  • Clinical diagnosis is an important factor in facilitating the urgent excision of squamous cell carcinomas (SCC) and malignant melanomas.
  • OBJECTIVES: To identify the numbers and types of malignant skin tumours managed in an NHS teaching hospital and to assess the diagnostic accuracy.
  • METHODS: Data were collected on every histologically proven malignant skin lesion over a 6-month period.
  • RESULTS: One thousand one hundred and ninety-five malignant skin tumours were identified: 78% were basal cell carcinomas, 14% were SCC, 6% were malignant melanomas and the remaining 2% included Merkel cell tumours, malignant adnexal tumours and lentigo maligna.
  • The correct clinical diagnosis had been made by the secondary care clinician in 84% of cases but an incorrect clinical diagnosis was given in 32% of SCC.
  • CONCLUSIONS: The majority of skin malignancies (968 of 1195, 81%) were managed by dermatologists.
  • Where primary excision was attempted, this was complete in 91% (767 of 916) of cases.
  • The correct clinical diagnosis was made in 84% of all tumours, but 32% of SCC were not correctly diagnosed prior to surgery.
  • [MeSH-major] Clinical Competence. Dermatology. Patient Selection. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery
  • [MeSH-minor] Biopsy. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Databases, Factual. England. Humans. Melanoma / diagnosis. Melanoma / surgery. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16792759.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Brownell I: Nodular basal cell carcinoma: when in doubt, cut it out. J Drugs Dermatol; 2007 Dec;6(12):1245-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular basal cell carcinoma: when in doubt, cut it out.
  • Treating superficial basal cell carcinomas (BCCs) with photodynamic therapy or topical imiquimod can provide effective results in situations where an excisional approach is contraindicated or undesirable.
  • Numerous studies have sought to test these treatments for nodular BCCs.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189068.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod
  •  go-up   go-down


10. Shivakumar D, Deng Y, Roux B: Computations of Absolute Solvation Free Energies of Small Molecules Using Explicit and Implicit Solvent Model. J Chem Theory Comput; 2009 Apr 14;5(4):919-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of the crucial role of electrostatics in solvation free energy, the results from various commonly used charge generation models based on the semiempirical (AM1-BCC) and QM calculations [charge fitting using ChelpG and RESP] are compared.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26609601.001).
  • [ISSN] 1549-9618
  • [Journal-full-title] Journal of chemical theory and computation
  • [ISO-abbreviation] J Chem Theory Comput
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Romaní J, Yébenes M: [Repair of surgical defects of the nasal pyramid]. Actas Dermosifiliogr; 2007 Jun;98(5):302-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Resolución de los defectos quirúrgicos de la pirámide nasal.
  • Basal cell and squamous cell carcinoma frequently affect the nasal appendix and its adjacent structures.
  • Small surgical defects may be repaired by direct closure or second intention healing but local flaps and skin grafts from appropriate donor sites are frequently required after excision of tumors.
  • Flaps offer similar skin in terms of color, texture and photoaging.
  • [MeSH-minor] Humans. Reconstructive Surgical Procedures / methods. Skin Transplantation. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555672.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 14
  •  go-up   go-down


12. Lally A, Bowling J: Contrasting vascular patterns: a helpful dermoscopic feature for identifying basal cell carcinoma within port wine stains. Dermatol Surg; 2010 Jun;36(6):950-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrasting vascular patterns: a helpful dermoscopic feature for identifying basal cell carcinoma within port wine stains.
  • [MeSH-major] Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Facial Neoplasms / blood supply. Port-Wine Stain / pathology. Skin Neoplasms / blood supply. Skin Neoplasms / pathology
  • [MeSH-minor] Dermoscopy. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482729.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kritz-Silverstein D, Schneider DL, Sandwell J: Breast cancer and bone mass in older women: is bone density prescreening for mammography useful? Osteoporos Int; 2006;17(8):1196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer and bone mass in older women: is bone density prescreening for mammography useful?
  • This case-control study compares BMD at multiple sites in women with and without breast cancer to determine if BMD prescreening is useful in selecting women for continued screening mammograms.
  • METHODS: Women diagnosed with breast cancer in the preceding 4 months and age-matched controls (+/-2 years) with a normal mammogram, all aged 65 years and older, were recruited on a 1:2 basis; 237 women participated: 79 women (cases) with breast cancer and 158 controls.
  • RESULTS: Among women with breast cancer, 17.1% had stage 0, 41.5% stage I, 40.0% stage II, and 1.4% stage III.
  • Women with breast cancer had larger waist circumferences (p=0.002) and waist-hip ratios (p=0.01), and they exercised less (p=0.002) than women of the control group.
  • However, there were no differences between the cases and controls for age, obesity, and reproductive and menopausal history variables, or other covariates (p>0.10).
  • There were no differences in lumbar spine, total hip, femoral neck, midshaft radius, or total body BMD (p>0.10), although the cases had higher BMD at the ultradistal radius than the controls (means: 0.527 vs. 0.516, respectively; p=0.014).
  • There were no differences in breast cancer risk by tertile of BMD or osteoporosis status at the hip or spine.
  • CONCLUSION: There is little difference in BMD between women with and without breast cancer.
  • BMD is not useful as a prescreening predicator of mammography in older women and using it as such would result in cases of breast cancer being missed.
  • [MeSH-major] Bone Density. Breast Neoplasms / etiology. Mammography
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Exercise. Female. Humans. Risk Factors. Vitamin D / administration & dosage

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone. 2003 Mar;32(3):211-6 [12667548.001]
  • [Cites] Cancer Causes Control. 1994 Nov;5(6):523-8 [7827239.001]
  • [Cites] Am J Epidemiol. 1990 Nov;132(5):877-83 [2239902.001]
  • [Cites] Environ Health Perspect. 1997 Apr;105 Suppl 3:583-5 [9167999.001]
  • [Cites] JAMA. 1999 Dec 8;282(22):2156-63 [10591338.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1118-23 [7714079.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 3;90(11):814-23 [9625169.001]
  • [Cites] Am J Epidemiol. 2001 Jun 1;153(11):1071-8 [11390325.001]
  • [Cites] Endocr Rev. 1994 Jun;15(3):275-300 [8076582.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):190-7 [7707406.001]
  • [Cites] Ann Intern Med. 1997 Dec 1;127(11):955-65 [9412300.001]
  • [Cites] World Health Organ Tech Rep Ser. 1994;843:1-129 [7941614.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):533-9 [8827358.001]
  • [Cites] Science. 1988 Jul 1;241(4861):84-6 [3388021.001]
  • [Cites] JAMA. 1996 Nov 6;276(17):1404-8 [8892715.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):930-6 [11416114.001]
  • [Cites] Bone Miner. 1993 Feb;20(2):141-9 [8453330.001]
  • [Cites] J Clin Epidemiol. 2001 Apr;54(4):417-22 [11297892.001]
  • [Cites] Environ Health Perspect. 1997 Apr;105 Suppl 3:593-9 [9168001.001]
  • [Cites] J Chronic Dis. 1987;40(2):105-13 [3818863.001]
  • [Cites] J Am Acad Nurse Pract. 2001 Jun;13(6):276-84 [11930870.001]
  • [Cites] N Engl J Med. 1997 Feb 27;336(9):611-7 [9032046.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1163-74 [9849474.001]
  • [Cites] JAMA. 1999 Jun 16;281(23):2189-97 [10376571.001]
  • (PMID = 16699738.001).
  • [ISSN] 0937-941X
  • [Journal-full-title] Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  • [ISO-abbreviation] Osteoporos Int
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00827
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  •  go-up   go-down


14. Misago N, Mori T, Narisawa Y: Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Nov;24(11):1354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma.
  • BACKGROUND: Both trichoblastoma and basal cell carcinoma (BCC) are considered to be a benign and malignant neoplasm of follicular germinative cells respectively.
  • OBJECTIVE: The aim of the present study was to investigate whether trichoblastoma and BCC recapitulate the epithelial–mesenchymal interactions in embryonic hair germs or early anagen hair follicles by expressing nestin in stromal cells.
  • METHODS: Immunohistochemical staining was performed with antibody against nestin for 15 trichoblastomas including large/small nodular, retiform and trichoepithelioma types, while adding the superficial type associated with nevus sebaceous and for 20 BCCs including superficial, nodular, nodulo-infiltrative, and infiltrative/micronodular types.
  • In all 20 BCCs, the stromal cells were basically negative for nestin.
  • CONCLUSIONS: The development of trichoblastomas incompletely recapitulates the epithelial–mesenchymal interactions in embryonic hair germs or early anagen hair follicles, whereas BCCs fundamentally have lost this ability.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. Sebaceous Gland Neoplasms / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337823.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


15. Babilas P, Karrer S, Sidoroff A, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology--an update. Photodermatol Photoimmunol Photomed; 2005 Jun;21(3):142-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical photodynamic therapy (PDT) is a well-established treatment modality which has mainly shown to be effective for dermatooncologic conditions like actinic keratoses (AK), Bowen's disease, in situ squamous cell carcinoma and superficial basal cell carcinoma (BCC).
  • Depending on the applied light dose and the concentration of the photosensitizer either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving the inflammatory conditions occur.
  • [MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888131.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 56
  •  go-up   go-down


16. de Villiers EM, Sandstrom RE, zur Hausen H, Buck CE: Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast. Breast Cancer Res; 2005;7(1):R1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast.
  • BACKGROUND: Viruses including Epstein-Barr virus (EBV), a human equivalent of murine mammary tumour virus (MMTV) and human papillomavirus (HPV) have been implicated in the aetiology of human breast cancer.
  • We report the presence of HPV DNA sequences in areolar tissue and tumour tissue samples from female patients with breast carcinoma.
  • The presence of virus in the areolar-nipple complex suggests to us a potential pathogenic mechanism.
  • METHODS: Polymerase chain reaction (PCR) was undertaken to amplify HPV types in areolar and tumour tissue from breast cancer cases.
  • RESULTS: Papillomavirus DNA was present in 25 of 29 samples of breast carcinoma and in 20 of 29 samples from the corresponding mamilla.
  • The most prevalent type in both carcinomas and nipples was HPV 11, followed by HPV 6.
  • Other types detected were HPV 16, 23, 27 and 57 (nipples and carcinomas), HPV 20, 21, 32, 37, 38, 66 and GA3-1 (nipples only) and HPV 3, 15, 24, 87 and DL473 (carcinomas only).
  • Multiple types were demonstrated in seven carcinomas and ten nipple samples.
  • CONCLUSIONS: The data demonstrate the occurrence of HPV in nipple and areolar tissues in patients with breast carcinoma.
  • [MeSH-major] Breast Neoplasms / virology. Carcinoma / virology. Nipples / virology. Papillomaviridae / genetics. Papillomaviridae / pathogenicity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1992 Apr;188(3):384-6 [1320761.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] Cancer Res. 1992 Nov 1;52(21):5872-8 [1327518.001]
  • [Cites] EMBO J. 1993 May;12(5):1847-52 [8387914.001]
  • [Cites] J Gen Virol. 1994 May;75 ( Pt 5):1157-62 [8176376.001]
  • [Cites] Curr Top Microbiol Immunol. 1994;186:1-12 [8205835.001]
  • [Cites] J Dermatol. 1994 Oct;21(10):709-15 [7798425.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7829-33 [7644500.001]
  • [Cites] Virology. 1996 Jun 1;220(1):1-9 [8659100.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(2):197-202 [8872328.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Breast Cancer Res Treat. 1996;41(1):51-7 [8932876.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):961-5 [8959317.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):356-61 [9359482.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1793-801 [9528751.001]
  • [Cites] J Virol. 2001 Dec;75(23):11791-802 [11689660.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Hum Virol. 2001 Nov-Dec;4(6):329-34 [12082399.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):214-9 [12115572.001]
  • [Cites] J Virol. 2002 Oct;76(20):10559-68 [12239337.001]
  • [Cites] Lancet. 2002 Oct 5;360(9339):1044-9 [12383984.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):304-7 [12397656.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1234-45 [12439712.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2571-6 [12467072.001]
  • [Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1832-6 [12488476.001]
  • [Cites] J Virol. 2003 Jan;77(2):1551-63 [12502868.001]
  • [Cites] J Med Virol. 2004 Mar;72(3):473-7 [14748072.001]
  • [Cites] Int J Cancer. 2004 Mar 20;109(2):253-8 [14750177.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]
  • [Cites] Int J Cancer. 1982 Feb 15;29(2):143-6 [6277807.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):575-8 [2997044.001]
  • [Cites] J Virol. 1986 Jan;57(1):353-6 [3001357.001]
  • [Cites] J Virol. 1986 Jun;58(3):963-6 [3009899.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1832-5 [2820563.001]
  • [Cites] Virology. 1988 Jul;165(1):225-33 [2838960.001]
  • [Cites] Virology. 1989 Nov;173(1):284-90 [2554574.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):463-7 [2153303.001]
  • [Cites] Br J Dermatol. 1990 Jun;122(6):757-62 [2164414.001]
  • [Cites] Am J Clin Pathol. 1991 Feb;95(2):117-24 [1846996.001]
  • [Cites] Virology. 1991 Nov;185(1):484-7 [1656601.001]
  • [Cites] Br J Cancer. 1992 Jun;65(6):891-4 [1319728.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):752-5 [9579540.001]
  • [Cites] Laryngoscope. 1998 May;108(5):735-40 [9591556.001]
  • [Cites] Biomed Pharmacother. 1998;52(1):26-33 [9755792.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):681-4 [10048966.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):225-8 [10188723.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(2):121-35 [10326789.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2201-11 [10327066.001]
  • [Cites] J Gen Virol. 1999 Jun;80 ( Pt 6):1513-7 [10374970.001]
  • [Cites] J Virol. 1999 Sep;73(9):7297-307 [10438818.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1349-50 [10451431.001]
  • [Cites] J Gen Virol. 1999 Sep;80 ( Pt 9):2437-43 [10501499.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):369-77 [10606184.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):413-22 [10712888.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):14824-30 [10809724.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):697-703 [10919740.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):33-6 [11029768.001]
  • [Cites] J Virol. 2000 Dec;74(24):11636-41 [11090162.001]
  • [Cites] J Virol. 2001 Jan;75(1):151-60 [11119584.001]
  • [Cites] Arch Virol. 2001;146(1):171-80 [11266212.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):797-801 [11299846.001]
  • [Cites] Breast Cancer Res Treat. 1992;21(2):95-100 [1320958.001]
  • (PMID = 15642157.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC1064094
  •  go-up   go-down


17. Beatty JD, Atwood M, Tickman R, Reiner M: Metaplastic breast cancer: clinical significance. Am J Surg; 2006 May;191(5):657-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast cancer: clinical significance.
  • BACKGROUND: Metaplastic breast carcinoma (MBC) is a rare poorly differentiated breast cancer characterized by coexistence of ductal carcinoma with areas of matrix producing, spindle-cell, sarcomatous, or squamous differentiation; ER/PR/HER2 negativity; and a reputation for poor outcome.
  • METHODS: The Swedish Cancer Institute prospective breast cancer database (> 6500 patients; 1990-2005) has 24 MBC cases that were compared with typical breast cancer cases matched for age, date of diagnosis, stage, and ER/PR/HER2 status.
  • The histological/nuclear grade was high in 21 of 24 cases.
  • ER and/or PR receptor status was negative in all cases.
  • HER2 was negative in 10 of 11 cases tested.
  • EGFR (HER1) was positive in 7 of 7 cases tested.
  • Four patients had distant recurrences 5 to 88 months from diagnosis.
  • Comparison with matched typical breast cancer cases revealed no major significant difference in multidisciplinary treatment patterns, recurrence, or survival.
  • CONCLUSION: MBC is associated with poor prognostic indicators, but outcomes comparable with matched typical breast cancer cases can be achieved with routine aggressive multidisciplinary care.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Metastasis. Prospective Studies. Risk Factors. Survival Rate. Sweden / epidemiology


18. Pezeshki A, Sari-Aslani F, Ghaderi A, Doroudchi M: p53 codon 72 polymorphism in basal cell carcinoma of the skin. Pathol Oncol Res; 2006;12(1):29-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 codon 72 polymorphism in basal cell carcinoma of the skin.
  • Basal cell carcinoma (BCC) is the most prevalent cancer in Iran.
  • In the present study the frequency of p53 codon 72 polymorphism in 91 patients with BCC of skin, compared to 465 healthy normal individuals, was investigated.
  • However, there was an apparent increase in the Arg/Arg genotype among those BCC patients who had a history of occupational sun exposure, compared to non-exposed patients (46.3% vs. 23.1%, P=0.11).
  • Our results suggest that Arg allele at codon 72 of p53 gene might affect the risk of ultraviolet-induced basal cell carcinoma.
  • [MeSH-major] Genes, p53 / genetics. Neoplasms, Basal Cell / genetics. Polymorphism, Genetic. Skin Neoplasms / genetics
  • [MeSH-minor] Codon. Environmental Exposure. Female. Genetic Predisposition to Disease. Humans. Iran. Male. Middle Aged. Occupational Exposure. Solar System. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2000 Apr;9(2):113-8 [10830578.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):684-90 [12628849.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2571-6 [12467072.001]
  • [Cites] Int J Cancer. 2000 Aug 15;87(4):528-33 [10918193.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Eur J Clin Invest. 2002 Dec;32(12):943-8 [12534455.001]
  • [Cites] Carcinogenesis. 1996 Feb;17(2):261-4 [8625447.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1385-7 [12820398.001]
  • [Cites] Int Arch Occup Environ Health. 2002 Apr;75(4):272-6 [11981662.001]
  • [Cites] Nat Genet. 2000 May;25(1):47-54 [10802655.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):2089-92 [14534749.001]
  • [Cites] Gene. 1988 Oct 30;70(2):245-52 [2905688.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4216-20 [8483937.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jul 1;109(1):63-6 [12818446.001]
  • [Cites] J Biomed Sci. 2003 Jul-Aug;10(4):430-5 [12824702.001]
  • [Cites] J Dermatol Sci. 2002 May;29(1):1-9 [12007715.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):444-9 [12911720.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):199-205 [12706878.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 2002 Apr;33(2):274-5 [12575207.001]
  • [Cites] J Invest Dermatol. 2002 Jul;119(1):84-90 [12164929.001]
  • [Cites] Cancer Lett. 2002 May 28;179(2):175-83 [11888672.001]
  • [Cites] Arch Dermatol. 2000 Feb;136(2):245-6 [10677101.001]
  • [Cites] Nat Med. 1997 May;3(5):510-4 [9142118.001]
  • [Cites] Transplantation. 2000 Mar 15;69(5):994-6 [10755564.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):515-7 [11238194.001]
  • (PMID = 16554913.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Codon
  •  go-up   go-down


19. Syeed N, Husain SA, Abdullah S, Sameer AS, Chowdri NA, Nanda MS, Siddiqi MA: Mutational profile of the CAV-1 gene in breast cancer cases in the ethnic Kashmiri population. Asian Pac J Cancer Prev; 2010;11(4):1099-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational profile of the CAV-1 gene in breast cancer cases in the ethnic Kashmiri population.
  • The role of caveolae and the caveolin proteins in cancer has been the subject of extensive research.
  • It has been suggested that Caveolin-1 may contribute to certain steps of carcinogenesis in various types of cancer.
  • Therefore in our study we focused on the potential clinical relevance of Caveolin-1 in 130 malignant breast tissue specimens along with their adjacent normal tissues.
  • Caveolin-1 was identified in a screen for genes involved in breast cancer progression and we demonstrated 29.2% mutational status in our Kashmiri ethnic population.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms, Male / genetics. Caveolin 1 / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133631.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / Codon, Nonsense
  •  go-up   go-down


20. Keir J: Re: Diagnosing skin cancer in primary care: how do main-stream general practitioners compare with primary care skin cancer clinic doctors? Med J Aust; 2008 Jan 21;188(2):125-6; author reply 126
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Diagnosing skin cancer in primary care: how do main-stream general practitioners compare with primary care skin cancer clinic doctors?
  • [MeSH-major] Ambulatory Care Facilities. Physicians, Family. Primary Health Care. Skin Neoplasms / diagnosis
  • [MeSH-minor] Australia. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Humans. Melanoma / diagnosis. Physical Examination

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18320613.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Australia
  •  go-up   go-down


21. Vidal CI, Goldberg M, Burstein DE, Emanuel HJ, Emanuel PO: p63 Immunohistochemistry is a useful adjunct in distinguishing sclerosing cutaneous tumors. Am J Dermatopathol; 2010 May;32(3):257-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though various immunohistochemical markers have proved useful, some cases remain a diagnostic challenge.
  • We aimed to assess the utility of p63 immunohistochemical staining in distinguishing microcystic adnexal carcinoma (MAC) from sclerosing basal cell carcinoma (SBCC) and desmoplastic trichoepithelioma (DTE).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Skin Appendage / diagnosis. Skin Neoplasms / diagnosis. Trans-Activators / analysis. Tumor Suppressor Proteins / analysis


22. Daneshbod Y, Daneshbod K, Khademi B: Diagnostic difficulties in the interpretation of fine needle aspirate samples in salivary lesions: diagnostic pitfalls revisited. Acta Cytol; 2009 Jan-Feb;53(1):53-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present our experience in diagnostic errors and pitfalls on aspiration cytology of salivary region in a high volume of cases.
  • These records and slides were reviewed to identify cytologic characteristics that contributed to false diagnosis.
  • RESULTS: Of a total of 1,040 salivary FNA samples, 376 cases had a final histologic diagnosis with interpretations of benign or malignant.
  • The sensitivity and specificity for correct interpretation of benign and malignant were 87% and 96%, respectively.
  • The most common false negative cases were acinic cell carcinoma, epithelial myoepithelial carcinoma, adenoid cystic carcinoma and basal cell adenocarcinoma.
  • Benign cases with false positive diagnosis were Warthin tumor and pleomorphic adenoma.
  • Selected positive and negative discordant cases are also discussed.
  • CONCLUSION: Knowledge of cytologic overlaps and pitfalls on salivary gland FNA, as well as clinical and radiologic features, may help clinicians arrive at the appropriate diagnosis and reduce false interpretations.
  • Several clinically important pitfalls with nonsalivary tumors of jaw and skin are demonstrated in our series.
  • [MeSH-major] Salivary Gland Neoplasms / diagnosis. Salivary Glands / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Child, Preschool. Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248555.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Morbidini-Gaffney S, Alpert TE, Hatoum GF, Sagerman RH: Benign pleural schwannoma secondary to radiotherapy for Hodgkin disease. Am J Clin Oncol; 2005 Dec;28(6):640-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pleural schwannoma secondary to radiotherapy for Hodgkin disease.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neurilemmoma / etiology. Pleural Neoplasms / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Carcinoma, Basal Cell / etiology. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Goiter, Nodular / etiology. Humans. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Skin Neoplasms / etiology. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317282.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


24. McKeon S, McClean S, Callaghan M: Macrophage responses to CF pathogens: JNK MAP kinase signaling by Burkholderia cepacia complex lipopolysaccharide. FEMS Immunol Med Microbiol; 2010 Oct;60(1):36-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage responses to CF pathogens: JNK MAP kinase signaling by Burkholderia cepacia complex lipopolysaccharide.
  • Burkholderia cepacia complex (Bcc) organisms pose a particular challenge in CF lung disease, due in part to their ability to trigger a fulminant pneumonia.
  • This study compares the U937 macrophage response to two Bcc species, B. cenocepacia and Burkholderia multivorans, against Pseudomonas aeruginosa and Staphylococcus aureus.
  • The two Bcc strains demonstrated higher levels of U937 macrophage internalization compared with both P. aeruginosa and S. aureus.
  • Both the Bcc strains also stimulated significantly greater levels of tumor necrosis factor-α and interleukin-1β from macrophages when compared with P. aeruginosa.
  • Further examination of the macrophage response to B. multivorans demonstrated that the lipopolysaccharide component of these bacteria was a potent inducer of proinflammatory cytokines and was shown to signal predominantly through the c-Jun N-terminal kinase mitogen-activated protein kinase pathway.
  • These studies further characterize the host response to Bcc and in particular B. multivorans, now the predominant Bcc species in many CF populations.
  • [MeSH-major] Burkholderia cepacia complex / immunology. Cytokines / secretion. JNK Mitogen-Activated Protein Kinases / metabolism. Lipopolysaccharides / immunology. Macrophages / immunology. Signal Transduction
  • [MeSH-minor] Cell Line. Cytoplasm / microbiology. Humans. Pseudomonas aeruginosa / immunology. Staphylococcus aureus / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.
  • (PMID = 20602636.001).
  • [ISSN] 1574-695X
  • [Journal-full-title] FEMS immunology and medical microbiology
  • [ISO-abbreviation] FEMS Immunol. Med. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Lipopolysaccharides; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


25. Love RR, Uy GB: Surgical oophorectomy for breast cancer: back to the future. Future Oncol; 2008 Dec;4(6):785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical oophorectomy for breast cancer: back to the future.
  • While the preponderance of current scientific presentations on breast cancer therapies has focused on chemotherapeutic strategies, targeted therapy with tyrosine kinase inhibitors and hormonal therapies for postmenopausal women, the majority of worldwide cases of breast cancer occur in premenopausal women, for whom practical inexpensive hormonal therapy, surgical oophorectomy, is the most common attainable treatment.
  • In hormone-receptor-positive breast cancer, meta-analysis data from older trials, and more specific recent trial data have made clearer the chronic natural history of this broad subtype of disease and the central role of hormonal therapy in its control.
  • Greater understanding of the critical variables in pathology procedures for breast tumor tissue hormonal receptor testing is leading to better definitions of the specific patients for whom hormonal therapies are indicated.
  • Closer examination of outcomes following surgical oophorectomy has suggested that more than just downregulation of estrogen stimulated breast cancer growth; the reduction of systemic estrogen levels also occurs with this procedure.
  • This combination of circumstances suggests that this first hormonal therapy for breast cancer may once again, have a much greater role globally.
  • [MeSH-major] Breast Neoplasms / surgery. Ovariectomy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19086845.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 44
  •  go-up   go-down


26. Chia KS: Gene-environment interactions in breast cancer. Novartis Found Symp; 2008;293:143-50; discussion 150-5, 181-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-environment interactions in breast cancer.
  • Breast cancer is one of the most frequently diagnosed cancers in women.
  • It accounts for 23% of all cancers, with an estimated 1.15 million new cases in 2002.
  • Breast cancers also tend to cluster in families and are more common in monozygotic twins.
  • Some of this clustering occurs as part of specific familial breast cancer syndromes where disease results from single alleles conferring a high risk.
  • However, such alleles are rare in the population, and highly penetrant variants of BRCA1 and BRCA2 account for less than 20% of the genetic risk of breast cancer.
  • The more common sporadic form of breast cancer are probably due to a polygenic inheritance of breast cancer susceptibility upon which environmental factors act upon resulting in breast cancer occurrence.
  • The lack of large prospective cohorts with thousands of incident breast cancer cases makes the study of gene-environment interactions using a nested case-control design extremely difficult.
  • [MeSH-major] Breast Neoplasms / etiology. Environment. Genes / physiology
  • [MeSH-minor] Female. Genetic Predisposition to Disease. Humans. Risk Factors


27. Zhang HT, Lu YF, Zeng J, Lin J, Liao QH, Wan FQ: [Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers]. Zhonghua Wai Ke Za Zhi; 2007 Apr 1;45(7):480-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers].
  • OBJECTIVE: To detect the mutations of BRCA1 and BRCA2 in sporadic breast cancer and study the relationship between BRCA1 and BRCA2 mutations and breast cancer.
  • METHODS: Breast cancer tissues of 144 patients and breast tissues of 30 cases of healthy people who were treated from December 2000 to September 2005 were studied.
  • RESULTS: A total of 20 single nucleotide changes in BRCA1 were detected in the 144 cases of breast cancer patients.
  • CONCLUSIONS: Mutations in BRCA1 may play an important role in evaluation of sick risk, earlier diagnosis and gene therapy of breast cancer in southern Chinese populations.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686308.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  •  go-up   go-down


28. Skeie G, Hjartåker A, Lund E: Diet among breast cancer survivors and healthy women. The Norwegian Women and Cancer Study. Eur J Clin Nutr; 2006 Sep;60(9):1046-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diet among breast cancer survivors and healthy women. The Norwegian Women and Cancer Study.
  • OBJECTIVE: To compare the diet and lifestyle in breast cancer survivors and healthy women.
  • DESIGN: Cross-sectional study in the population-based Norwegian Women and Cancer cohort study, using a postal questionnaire on diet, lifestyle and health.
  • Prevalent breast cancer cases (314 short-term with 1-5 years since diagnosis, 352 long-term with >5 years since diagnosis) were identified by linkage to the Norwegian Cancer Registry.
  • Short-term breast cancer survivors also had a higher use of dietary supplements and a lower level of physical activity, but did not differ from healthy women on other lifestyle factors.
  • CONCLUSION: Diet and lifestyle is generally similar between breast cancer survivors and healthy women, especially more than 5 years after diagnosis.
  • [MeSH-major] Breast Neoplasms / psychology. Diet Surveys. Food Habits / psychology. Health Status. Life Style

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 15 February 2006.
  • (PMID = 16482067.001).
  • [ISSN] 0954-3007
  • [Journal-full-title] European journal of clinical nutrition
  • [ISO-abbreviation] Eur J Clin Nutr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Yin R, Coull BA: Race/ethnicity and changing US socioeconomic gradients in breast cancer incidence: California and Massachusetts, 1978-2002 (United States). Cancer Causes Control; 2006 Mar;17(2):217-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race/ethnicity and changing US socioeconomic gradients in breast cancer incidence: California and Massachusetts, 1978-2002 (United States).
  • OBJECTIVE: We tested the hypothesis that the US socioeconomic gradient in breast cancer incidence is declining, with the decline most pronounced among racial/ethnic groups with the highest incidence rates.
  • METHODS: We geocoded the invasive incident breast cancer cases for three US population-based cancer registries covering: Los Angeles County, CA (1978-1982, 1988-1992, 1998-2002; n = 68,762 cases), the San Francisco Bay Area, CA (1978-1982, 1988-1992, 1998-2002; n = 37,210 cases) and Massachusetts (1988-1992, 1998-2002; n = 48,111 cases), linked the records to census tract area-based socioeconomic measures, and, for each socioeconomic stratum, computed average annual breast cancer incidence rates for the 5-year period straddling the 1980, 1990, and 2000 census, overall and by race/ethnicity and gender.
  • RESULTS: Our findings indicate that the socioeconomic gradient in breast cancer incidence is: (a) relatively small (at most 1.2) and stable among US white non-Hispanic and black women;.
  • CONCLUSION: Our results indicate that secular changes in US socioeconomic gradients in breast cancer incidence exist and vary by race/ethnicity.
  • [MeSH-major] Breast Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425100.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / CA / R01 CA095983-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Hadwin AM, Del Rio LF, Pinto LJ, Painter M, Routledge R, Moore MM: Microbial communities in wetlands of the Athabasca oil sands: genetic and metabolic characterization. FEMS Microbiol Ecol; 2006 Jan;55(1):68-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Naphthenic acids are a complex family of naturally occurring cyclic and acyclic carboxylic acids that are present in the acidic fraction of petroleum.
  • In contrast, cluster diagrams produced from the denaturing gradient gel electrophoresis data clearly separated bacterial communities according to naphthenic acids concentrations, indicating that naphthenic acids content was a major influence on the composition of the bacterial community.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NAPHTHENIC ACIDS .
  • Hazardous Substances Data Bank. NAPHTHENIC ACIDS, LEAD SALTS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420616.001).
  • [ISSN] 0168-6496
  • [Journal-full-title] FEMS microbiology ecology
  • [ISO-abbreviation] FEMS Microbiol. Ecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carboxylic Acids; 0 / DNA, Bacterial; 0 / Fatty Acids; 0 / Industrial Waste; 0 / Petroleum; 0 / Reagent Kits, Diagnostic; 1338-24-5 / naphthenic acid
  •  go-up   go-down


31. Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ: Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol; 2005 Nov;15(10):773-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival.
  • PURPOSE: To compare male and female breast cancer and to determine the predictors of tumor characteristics and survival in both genders.
  • METHODS: Male (n = 2923) and female breast cancer cases (n = 442,500) from the Surveillance, Epidemiology and End Results (SEER) registry were analyzed.
  • Cox proportional hazards regression modeling was used to determine significant predictors of death of breast cancer after adjusting for demographic factors.
  • RESULTS: Both men and women aged less than 50 years were at higher risk for advanced breast cancers.
  • The risk of breast cancer death among all cases was lower for each 10-year increase in age by 2%, higher for those who are unmarried than for those who are married by 12% and 13% higher for non-whites than for whites.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / pathology. SEER Program / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Functional Laterality. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Regression Analysis. Risk Factors. Sex Factors. Survival


32. Szabo P, Dam TK, Smetana K Jr, Dvoránková B, Kübler D, Brewer CF, Gabius HJ: Phosphorylated human lectin galectin-3: analysis of ligand binding by histochemical monitoring of normal/malignant squamous epithelia and by isothermal titration calorimetry. Anat Histol Embryol; 2009 Feb;38(1):68-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylated human lectin galectin-3: analysis of ligand binding by histochemical monitoring of normal/malignant squamous epithelia and by isothermal titration calorimetry.
  • We monitored normal and malignant squamous epithelia.
  • Basal cell carcinomas were invariably negative.
  • In all cases, binding was inhibitable by the presence of lactose, prompting further investigation of the activity of the lectin site by a sensitive biochemical method, i.e. isothermal titration calorimetry.
  • [MeSH-major] Epithelial Cells / chemistry. Epithelium / metabolism. Galectin 3 / metabolism. Neoplasms, Squamous Cell / metabolism. Phosphorylation

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983621.001).
  • [ISSN] 1439-0264
  • [Journal-full-title] Anatomia, histologia, embryologia
  • [ISO-abbreviation] Anat Histol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


33. Farhadi M, Kamrava SK, Behzadi AH, Rafiezadeh P, Asghari A, Rezvan F, Maleki S: The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma. J Drugs Dermatol; 2010 Feb;9(2):122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma.
  • OBJECTIVES: A number of investigations have already been carried out to assess the effect of photodynamic therapy (PDT) on primary basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions, but lack of investigations on recurrent lesions or lesions with treatment failure, prompted the authors to carry out this study.
  • The aim of the present study was to evaluate the efficacy of photodynamic therapy on recurrent BCC and SCC lesions on head and neck skin.
  • PATIENTS AND METHODS: A total of 30 patients, including 16 men and 14 women, were selected from patients with recurrent SCC and BCC who referred to Iran university ENT research center Rasool-e-Akram Hospital, Tehran-Iran, met the criteria and entered the study.
  • This is a longitudinal study of 30 patients with 43 histologically verified head and neck skin tumors, candidate for photodynamic therapy.
  • RESULTS: To cite the results obtained in this study, it is worth mention that five cases expressed disagreement with this treatment modality after the first session of illumination; the treatment was stopped because of pain or burning.
  • In a three-month evaluation, complete treatment response rates were obtained in 72% of patients (18 cases); in SCC cases it was 71.4% (10 cases) and in BCC it was 72.7% (eight cases).
  • The final result of complete response rate in three years of follow up, demonstrated that 16 (64%) patients out of 25 were disease-free from recurrent BCC and SCC (Table 1).
  • In BCC cases the final three-year response rate was seven (63.6%) and in SCC cases it was nine (64.2%).
  • Hence, there was no statistical difference between SCC and BCC cases to treatment (P = 0.34).
  • DISCUSSION: The obtained data from the current study is supportive of the recommended treatment method of PDT as an effective, tolerable and less invasive treatment in patients with recurrent BCC and SCC carcinomas, particularly when cosmetic effects are an important consideration.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy


34. Laska MJ, Nexø BA, Vistisen K, Poulsen HE, Loft S, Vogel U: Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer. Cancer Lett; 2005 Jul 28;225(2):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer.
  • Testicular cancer has been suggested to be primed in utero and there is familiar occurrence, particularly brothers and sons of men with testicular cancer have increased risk.
  • Although no specific causative genotoxic agents have been identified, variations in DNA repair capacity could be associated with the risk of testicular cancer.
  • A case-control study of 184 testicular cancer cases and 194 population-based controls living in the Copenhagen Greater Area in Denmark was performed.
  • We found that neither polymorphisms in several DNA repair genes nor alleles of several polymorphisms in the chromosomal of region 19q13.2-3, encompassing the genes ASE, ERCC1, RAI and XPD, were associated with risk of testicular cancer in Danish patients.
  • This is in contrast to other cancers, where we reported strong associations between polymorphisms in ERCC1, ASE and RAI and occurrence of basal cell carcinoma, breast cancer and lung.
  • To our knowledge this is the first study of DNA repair gene polymorphisms and risk of testicular cancer.
  • [MeSH-minor] Case-Control Studies. Denmark. Genetic Predisposition to Disease / genetics. Humans. Male. Repressor Proteins

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885892.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Nucleotides; 0 / PPP1R13L protein, human; 0 / Repressor Proteins
  •  go-up   go-down


35. Trzeciak S, Zanotti-Cavazzoni S, Parrillo JE, Dellinger RP: Inclusion criteria for clinical trials in sepsis: did the American College of Chest Physicians/Society of Critical Care Medicine consensus conference definitions of sepsis have an impact? Chest; 2005 Jan;127(1):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical trials published after the consensus conference (ACC; from 1993 to 2001) were compared with trials published before the consensus conference (BCC; from 1976 to 1992).
  • RESULTS: We identified 176 clinical trials (ACC, 119 trials; BCC, 57 trials).
  • The utilization of specified values for WBC count, temperature (T), heart rate (HR), and respiratory rate (RR) was significantly increased in the ACC group compared to the BCC group, as follows: WBC count, 62% vs 26%, respectively (p < 0.001); T, 89% vs 56%, respectively (p < 0.001); HR, 77% vs 26%, respectively (p < 0.001); and RR, respectively 76% vs 28% (p < 0.001).
  • (1) Since 1992 there has been a significant increase in the utilization of predefined sepsis criteria for patient enrollment in clinical trials, and this increase can be attributed to the existence of consensus conference definitions. (2) Compared to inclusion criteria BCC, inclusion criteria ACC were less reliant on blood culture positivity and were more likely to incorporate markers of organ dysfunction.
  • [MeSH-major] Clinical Trials as Topic / standards. Consensus Development Conferences as Topic. Patient Selection. Sepsis / diagnosis

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653990.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Meunier A, Truchon JF: Predictions of hydration free energies from continuum solvent with solute polarizable models: the SAMPL2 blind challenge. J Comput Aided Mol Des; 2010 Apr;24(4):361-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The usefulness of electronic polarization in predicting hydration free energies is assessed by comparing the Electronic Polarization from Internal Continuum model and the self consistent reaction field IEF-PCM to standard non-polarizable charge models such as RESP and AM1-BCC.

  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Phys Chem B. 2009 Apr 9;113(14):4501-7 [19338360.001]
  • [Cites] J Comput Chem. 2002 Dec;23(16):1623-41 [12395429.001]
  • [Cites] J Chem Theory Comput. 2009 Apr 14;5(4):919-30 [26609601.001]
  • [Cites] J Phys Chem B. 2008 Jan 24;112(3):938-46 [18171044.001]
  • [Cites] J Comput Chem. 2004 Jul 15;25(9):1157-74 [15116359.001]
  • [Cites] Biochim Biophys Acta. 2006 Nov;1764(11):1647-76 [17049320.001]
  • [Cites] J Chem Phys. 2007 Mar 7;126(9):094103 [17362100.001]
  • [Cites] J Chem Theory Comput. 2009 Jul 14;5(7):1785-1802 [24826083.001]
  • [Cites] Science. 1995 May 26;268(5214):1144-9 [7761829.001]
  • [Cites] J Chem Phys. 2007 Mar 28;126(12):124114 [17411115.001]
  • [Cites] J Chem Theory Comput. 2006 Jan;2(1):128-39 [26626387.001]
  • [Cites] J Chem Inf Model. 2007 Jan-Feb;47(1):122-33 [17238257.001]
  • [Cites] J Comput Chem. 2003 Jun;24(8):954-62 [12720316.001]
  • [Cites] J Med Chem. 2008 Feb 28;51(4):769-79 [18215013.001]
  • [Cites] Phys Rev A Gen Phys. 1988 Sep 15;38(6):3098-3100 [9900728.001]
  • [Cites] J Am Chem Soc. 2009 Oct 28;131(42):15403-11 [19778066.001]
  • [Cites] J Phys Chem B. 2009 Apr 9;113(14):4521-32 [19281198.001]
  • [Cites] J Comput Chem. 2004 Jan 30;25(2):265-84 [14648625.001]
  • [Cites] J Comput Chem. 2010 Mar;31(4):811-24 [19598266.001]
  • (PMID = 20354893.001).
  • [ISSN] 1573-4951
  • [Journal-full-title] Journal of computer-aided molecular design
  • [ISO-abbreviation] J. Comput. Aided Mol. Des.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Solutions; 0 / Solvents; A1TA934AKO / Xylose; IY9XDZ35W2 / Glucose; J64922108F / Benzene
  •  go-up   go-down


37. Cavalcante RB, Pereira KM, Nonaka CF, Nogueira RL, de Souza LB: Immunohistochemical expression of MMPs 1, 7, and 26 in syndrome and nonsyndrome odontogenic keratocysts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jul;106(1):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the presence of these proteases at higher levels in SOKCs may help to explain increased OKC aggressiveness associated with nevoid basal cell carcinoma syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / metabolism. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Matrix Metalloproteinases, Secreted / biosynthesis. Odontogenic Cysts / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18585626.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins; EC 3.4.24.- / MMP26 protein, human; EC 3.4.24.- / Matrix Metalloproteinases, Secreted; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


38. Betti R, Radaelli G, Bombonato C, Crosti C, Cerri A, Menni S: Anatomic location of Basal cell carcinomas may favor certain histologic subtypes. J Cutan Med Surg; 2010 Nov-Dec;14(6):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomic location of Basal cell carcinomas may favor certain histologic subtypes.
  • BACKGROUND: Differences in age, site, and subtype exist in basal cell carcinoma (BCC).
  • OBJECTIVE: To evaluate whether an independent association exists between the anatomic location and the histologic subtype of BCC.
  • MATERIALS AND METHODS: A series of 3,254 BCCs was examined.
  • RESULTS: Prevalence of BCCs on the head/neck or chest/abdomen increased with age (p < .001).
  • The prevalence of superficial subtype was lower among BCCs on the head/neck than other locations (24.9% vs 64.4%, OR 0.18, 95% CI 0.16-0.21).
  • The prevalence of nodular or morpheic/infiltrative subtype was higher among BCCs on the head/neck than other locations, that is, 57.1% versus 29.2%, OR 3.23, 95% CI 2.79 to 3.74 (nodular) and 16.1% versus 4.0%, OR 4.56, 95% CI 3.42 to 6.08 (morpheic/infiltrative).
  • CONCLUSION: Anatomic location and subtype of BCC were associated with age, but the anatomic location was the only independent predictor of histologic subtype.
  • Although a bias by referral patterns may not be excluded, the results suggest that the anatomic location may favor the development of particular BCC subtypes.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084023.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Vanhaecke L, Grootaert C, Verstraete W, Van de Wiele T: Chemopreventive effects from prebiotic inulin towards microbial 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine bioactivation. J Appl Microbiol; 2009 Feb;106(2):474-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, the production of short-chain fatty acids increased with 12%, 3% and 7%, while ammonia concentrations decreased with 3%, 4% and 3% in the ascending, transverse and descending colon compartments, respectively.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200315.001).
  • [ISSN] 1365-2672
  • [Journal-full-title] Journal of applied microbiology
  • [ISO-abbreviation] J. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 7-hydroxy-5-methyl-3-phenyl-6,7,8,9-tetrahydropyrido(3',2'-4,5)imidazo(1,2-a)pyrimidin-5-ium; 0 / Fatty Acids, Volatile; 0 / Imidazoles; 0 / Mutagens; 0 / Prebiotics; 0 / Pyrimidines; 9005-80-5 / Inulin; 909C6UN66T / 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  •  go-up   go-down


40. Folman LB, Klein Gunnewiek PJ, Boddy L, de Boer W: Impact of white-rot fungi on numbers and community composition of bacteria colonizing beech wood from forest soil. FEMS Microbiol Ecol; 2008 Feb;63(2):181-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of white-rot fungi on numbers and community composition of bacteria colonizing beech wood from forest soil.
  • White-rot fungi are important wood-decomposing organisms in forest ecosystems.
  • Their ability to colonize and decompose woody resources may be strongly influenced by wood-inhabiting bacteria that grow on easily utilizable compounds e.g. oligomers of wood-polymers released by fungal enzymes.
  • However, so far, it is not known how white-rot fungi deal with the presence of potential competing bacteria.
  • Here, the effects of two white-rot fungi, Hypholoma fasciculare and Resinicium bicolor, on the numbers and composition of bacteria colonizing sterile beech wood blocks from forest soil are reported.
  • Both total numbers (microscopic counts) and the numbers of cultivable wood-inhabiting bacteria were considerably lower in wood blocks that became colonized by the white-rot fungi than in control blocks.
  • This points to the fungi out-competing the opportunistic bacteria.
  • The presence of white-rot fungi resulted in a change in the relative abundance of families of cultivable bacteria in wood and also in a change of denaturing gradient gel electrophoresis patterns of directly amplified 16S rRNA gene fragments.
  • Analysis of the bacterial community structure in soil adhering to exploratory mycelium (cords) indicated that fungal species-specific effects on bacterial community composition were also apparent in this fungal growth phase.
  • [MeSH-major] Bacteria / isolation & purification. Basidiomycota. Soil Microbiology. Wood / microbiology
  • [MeSH-minor] Base Sequence. Colony Count, Microbial. Fagus / microbiology. Molecular Sequence Data. Phylogeny. RNA, Bacterial / genetics. RNA, Ribosomal, 16S / genetics. Sequence Analysis, RNA

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199083.001).
  • [ISSN] 0168-6496
  • [Journal-full-title] FEMS microbiology ecology
  • [ISO-abbreviation] FEMS Microbiol. Ecol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF027740/ EF027741/ EF027742/ EF027743/ EF027744/ EF027745/ EF027746/ EF027747/ EF027748/ EF027749/ EF027750/ EF027751/ EF027752/ EF027753/ EF027754/ EF027755/ EF027756/ EF027757/ EF027758/ EF027759/ EF027760/ EF027761/ EF027762/ EF027763/ EF027764/ EF027765/ EF027766/ EF027767/ EF027768/ EF027769/ EF027770/ EF027771/ EF027772/ EF027773/ EF027774/ EF027775/ EF027776/ EF027777/ EF027778/ EF027779/ EF027780/ EF027781/ EF027782/ EF027783/ EF027784/ EF027785/ EF027786/ EF027787/ EF027788/ EF027789/ EF027790/ EF027791/ EF027792/ EF027793/ EF027794/ EF027795/ EF027796/ EF027797/ EF027798/ EF027799/ EF027800/ EF027801/ EF027802/ EF027803/ EF027804/ EF027805/ EF027806/ EF027807/ EF027808/ EF027809/ EF027810/ EF027811/ EF027812/ EF027813/ EF027814/ EF027815/ EF027816/ EF027817/ EF027818/ EF027819/ EF027820/ EF027821/ EF027822/ EF027823/ EF027824/ EF027825/ EF027826/ EF027827/ EF027828/ EF027829/ EF027830/ EF027831/ EF027832/ EF027833/ EF027834/ EF027835/ EF027836/ EF027837/ EF027838/ EF027839/ EF027840/ EF027841/ EF027842/ EF027843/ EF027844/ EF027845/ EF027846/ EF027847/ EF027848/ EF027849/ EF027850/ EF027851/ EF027852/ EF027853/ EF027854/ EF027855/ EF027856/ EF027857/ EF027858
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Bacterial; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


41. Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, Bellach J, Dahl E, Dietel M, Kristiansen G: Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol; 2007 11;22(11):1221-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
  • Gross cystic disease fluid protein (GCDFP-15) and mammaglobin are both widely used and accepted markers for epithelia of breast origin.
  • We aimed to evaluate their relation of expression on parallel whole tissue sections in primary breast cancer by immunohistochemistry and also to correlate it with clinico-pathological parameters including patient survival.
  • Primary breast carcinomas from 165 patients with a mean clinical follow-up of 73 months were immunostained using commercially available antibodies against GCDFP-15 and mammaglobin.
  • Cytoplasmic expression of GCDFP-15 and mammaglobin was observed in 73.3% and 72.1% of invasive breast carcinomas respectively.
  • 91.8% of breast cancer cases expressed at least one of both markers.
  • Additionally, GCDFP-15 negativity was significantly associated with shortened disease-free survival times in univariate and multivariate analyses.
  • We demonstrated the strong correlation of GCDFP-15 and mammaglobin with each other and showed that only very few primary breast cancers are completely negative for both markers.
  • The significantly longer disease free survival times for patients with GCDFP-15 positive tumours clearly warrants further study.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Lobular / metabolism. Carrier Proteins / metabolism. Glycoproteins / metabolism. Neoplasm Proteins / metabolism. Uteroglobin / metabolism
  • [MeSH-minor] Cell Count. Disease-Free Survival. Female. Humans. Mammaglobin A. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17647195.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / PIP protein, human; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


42. Gautier T, Tietge UJ, Boverhof R, Perton FG, Le Guern N, Masson D, Rensen PC, Havekes LM, Lagrost L, Kuipers F: Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein. J Lipid Res; 2007 Jan;48(1):30-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to the expected moderate reduction in plasma cholesterol levels, apoCIKO mice showed significant increases in the hepatic content of cholesteryl esters (+58%) and triglycerides (+118%) and in biliary cholesterol concentration (+35%) as compared with wild-type mice.
  • Biliary levels of cholesterol, phospholipids, and bile acids were increased by 88, 77, and 20%, respectively, whereas total cholesterol, HDL cholesterol, and triglyceride concentrations in plasma were further reduced in CETPTg/apoCIKO mice versus CETPTg mice.
  • In line with the previously recognized inhibition of lipoprotein clearance by apoC-I, apoC-I deficiency led to decreased plasma lipid concentration, hepatic lipid accumulation, and increased biliary excretion of cholesterol.
  • The effect was even greater when the alternate reverse cholesterol transport pathway via VLDL/LDL was boosted in the presence of CETP.
  • [MeSH-major] Apolipoprotein C-I / deficiency. Cholesterol Ester Transfer Proteins / metabolism. Lipids / physiology. Liver / metabolism


43. Galimberti G, Pontón Montaño A, Ferrario D, Kowalczuk A, Galimberti R: [Mohs micrographic surgery for the treatment of basal cell carcinoma]. Actas Dermosifiliogr; 2010 Dec;101(10):853-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mohs micrographic surgery for the treatment of basal cell carcinoma].
  • [Transliterated title] Cirugía micrográfica de Mohs en el tratamiento de carcinoma basocelular.
  • INTRODUCTION: Basal cell carcinoma accounts for 75% of all nonmelanoma skin cancer.
  • Here, we evaluate the efficacy of Mohs micrographic surgery for the treatment of basal cell carcinoma.
  • MATERIAL AND METHODS: A retrospective review of cases of basal cell carcinoma treated with Mohs micrographic surgery between October 2003 and June 2009 was performed using patient records from Hospital Italiano in Buenos Aires, Argentina.
  • RESULTS: A total of 2412 basal cell carcinomas treated with Mohs micrographic surgery were identified; 50.5% were in women and 49.5% in men.
  • The histologic type of the tumor was solid in 65.3% of cases and in 89% of cases the tumor was located on the head or neck.
  • Over a mean follow-up of 32 months, there were 9 cases of tumor recurrence (0.37%).
  • CONCLUSIONS: In our experience, Mohs micrographic surgery is effective for the treatment of high-risk basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159261.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


44. Grant WB: Re: Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst; 2009 Feb 4;101(3):210; author reply 210-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Nonmelanoma skin cancer and risk for subsequent malignancy.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Neoplasms, Second Primary / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Natl Cancer Inst. 2008 Sep 3;100(17):1215-22 [18728282.001]
  • (PMID = 19176462.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


45. Abdulla FR, Feldman SR, Williford PM, Krowchuk D, Kaur M: Tanning and skin cancer. Pediatr Dermatol; 2005 Nov-Dec;22(6):501-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tanning and skin cancer.
  • Skin cancer is a large and growing problem in the United States.
  • Sun and other ultraviolet (UV) light exposures play a key role in the development of skin cancer.
  • Pediatricians can play an important role in counseling patients and are in a position to help educate children and their families about skin cancer.
  • The purpose of this review is to familiarize pediatricians with the magnitude of the skin cancer problem and the evidence that ultraviolet light exposure, particularly indoor tanning, contributes to this problem.
  • We reviewed the literature on ultraviolet light and skin cancer (based on a MEDLINE search of articles using the headings "ultraviolet light" and "skin cancer") and found that skin cancer is the most rapidly growing cause of cancer deaths in the United State.
  • There is strong epidemiologic evidence for the relationship between UV exposure and nonmelanoma skin cancer and growing evidence for the relationship between indoor tanning and melanoma.
  • [MeSH-major] Melanoma / etiology. Skin Neoplasms / etiology. Sunlight / adverse effects. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adolescent. Age Factors. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Child. Child, Preschool. Female. Humans. Incidence. Male. Prognosis. Risk Assessment. Skin Pigmentation / physiology. Sunburn / epidemiology. Sunburn / prevention & control. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354251.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


46. Yuan L, Goldbach A, Xu H: Segregation and H2 transport rate control in body-centered cubic PdCu membranes. J Phys Chem B; 2007 Sep 20;111(37):10952-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The membrane underwent a bcc-fcc (body-centered cubic to face-centered cubic) phase transition between 723 and 873 K resulting in compositional segregation.
  • After reannealing at 723 K the alloy layer reverted to a bcc structure although a small fcc fraction remained behind.
  • The mixed-phase morphology was analyzed combining X-ray diffraction with scanning electron microscopy-energy-dispersive spectroscopic analysis (SEM-EDS) measurements, which revealed micrometer-scale Cu-enriched bcc and Cu-depleted fcc domains.
  • The prevalence of desorption as the permeation rate-limiting step below 454 K is attributed to the pairing of an extraordinarily high hydrogen diffusivity with a marginal hydrogen solubility in bcc PdCu alloys.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715958.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Pajares Hachero B, Torres Sánchez E, Vicioso L, Gallego E, Jiménez B, Alba Conejo E: Metastatic basal cell carcinoma and Turner syndrome: an unusual coincidence. Eur J Dermatol; 2010 Nov-Dec;20(6):848-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma and Turner syndrome: an unusual coincidence.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology. Turner Syndrome / complications


48. Felder S, Rabinovitz H, Oliviero M, Kopf A: Dermoscopic pattern of pigmented basal cell carcinoma, blue-white variant. Dermatol Surg; 2006 Apr;32(4):569-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic pattern of pigmented basal cell carcinoma, blue-white variant.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Dermoscopy. Skin Neoplasms / diagnosis


49. Green AC, McBride P: Squamous cell carcinoma of the skin (non-metastatic). BMJ Clin Evid; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the skin (non-metastatic).
  • INTRODUCTION: Cutaneous squamous cell carcinoma is a malignant tumour of keratinocytes arising in the epidermis, with histological evidence of dermal invasion.
  • Incidence varies by country and skin colour, and is as high as 400/100,000 in Australia.
  • People with fair skin colour who sunburn easily without tanning, people with xeroderma pigmentosum, and people who are immunosuppressed are most susceptible to squamous cell carcinoma.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: Does the use of sunscreen help prevent cutaneous squamous cell carcinoma and solar keratosis?
  • What is the optimal margin for primary excision of cutaneous squamous cell carcinoma (non-metastatic)?
  • Does micrographically controlled surgery result in lower rates of local recurrence than standard primary excision in people with squamous cell carcinoma of the skin (non-metastatic)?
  • Does radiotherapy after surgery affect local recurrence of cutaneous squamous cell carcinoma in people with squamous cell carcinoma of the skin (non-metastatic)?
  • [MeSH-major] Carcinoma, Basal Cell. Neoplasm Recurrence, Local
  • [MeSH-minor] Carcinoma, Squamous Cell / epidemiology. Humans. Skin Neoplasms / epidemiology. Sunscreening Agents / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Med Surg. 2003 Jul-Aug;7(4):300-5 [12879331.001]
  • [Cites] Surg Gynecol Obstet. 1966 Feb;122(2):245-8 [5901291.001]
  • [Cites] Arch Surg. 1974 Jan;108(1):50-1 [4808574.001]
  • [Cites] Cancer. 1989 May 1;63(9):1863-71 [2702595.001]
  • [Cites] Am J Clin Oncol. 1991 Oct;14(5):383-6 [1951174.001]
  • [Cites] J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):467-84 [1564155.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):574-7 [1463102.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):512-8 [8504041.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Nov;113(5):589-96 [7478649.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):89-93 [10758309.001]
  • [Cites] Aust N Z J Surg. 2000 May;70(5):358-61 [10830600.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1061-9 [11240248.001]
  • [Cites] Arch Dermatol. 2003 Apr;139(4):451-5 [12707092.001]
  • [Cites] Plast Reconstr Surg. 2003 Jul;112(1):57-63 [12832877.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):124-30 [8606543.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):628-34 [9610717.001]
  • [Cites] J Am Acad Dermatol. 1998 Jun;38(6 Pt 1):960-6 [9632005.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1304-9 [10433619.001]
  • [Cites] Head Neck. 1999 Sep;21(6):526-30 [10449668.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Med J Aust. 2006 Jan 2;184(1):6-10 [16398622.001]
  • [Cites] Prev Med. 2006 Mar;42(3):171-6 [16325898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1301-7 [17535230.001]
  • [Cites] Int Arch Occup Environ Health. 2009 Feb;82(3):357-63 [18649084.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2009 Apr;62(4):457-61 [18218349.001]
  • (PMID = 21733203.001).
  • [ISSN] 1752-8526
  • [Journal-full-title] BMJ clinical evidence
  • [ISO-abbreviation] BMJ Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  • [Other-IDs] NLM/ PMC2907617
  •  go-up   go-down


50. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El-Naggar AK, Prieto VG, Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q: Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res; 2007 Nov 1;13(21):6532-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression.
  • PURPOSE: To examine the role of suboptimal DNA repair capacity (DRC) for UV light-induced DNA damage in the development of nonmelanoma skin cancer (NMSC) and tumor progression.
  • EXPERIMENTAL DESIGN: We conducted a hospital-based case-control study of 255 patients with newly diagnosed NMSC [146 with basal cell carcinoma (BCC) and 109 with squamous cell carcinoma (SCC)] and 333 cancer-free controls.
  • We collected information on demographic variables and risk factors from questionnaires, tumor characteristics from medical records, and lymphocytic DRC phenotype by the host-cell reactivation assay.
  • RESULTS: Overall, there was a relative 16% reduction in DRC in NMSC patients compared with controls (P < 0.001 for BCC and for SCC, respectively).
  • DRC below the controls' median value was associated with increased risk significantly for BCC (OR, 1.62; 95% CI, 1.07-2.45) but borderline for SCC (OR, 1.63; 95% CI, 0.95-2.79) after adjustment for age, sex, and other assay-related covariates.
  • When the highest tertile of controls' DRC was used as the reference, the intermediate and low DRC were associated with a statistically significant trend for increasing risk for both BCC (P(trend) = 0.007) and SCC (P(trend) = 0.020).
  • CONCLUSIONS: Reduced DRC is an independent risk factor for BCC and single or nonaggressive SCC but not for multiple primaries, local aggressiveness, or recurrence of NMSC.
  • [MeSH-major] DNA Damage. DNA Repair. Skin Neoplasms / etiology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Recurrence. Risk. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975167.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 100264; United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 68233; United States / NIEHS NIH HHS / ES / ES 11740
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


51. Hida Y, Kubo Y, Murao K, Arase S: Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res; 2007 May;299(2):103-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strong expression of a longevity-related protein, SIRT1, in Bowen's disease.
  • SIRT1 regulates cell survival via deacetylation of p53 and forkhead transcription factors, and overexpression of SIRT1 is reported to be essential for cell growth and survival in some kinds of cancer.
  • To elucidate the role of SIRT1 in human skin carcinogenesis, we have examined SIRT1 protein expression in 20 cases each of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), Bowen's disease (BD), and actinic keratosis (AK) by immunohistochemical analysis.
  • Overexpression of SIRT1 is frequently observed in all kinds of non-melanoma skin cancers included in this study.
  • In particular, strong expression was observed in all cases of BD.
  • In addition, no obvious difference between AK and SCC was observed in the expression of SIRT1, suggesting that overexpression of SIRT1 may have some relevance to the early stage of skin carcinogenesis.
  • We suppose that SIRT1 could be one of the critical targets for future therapy with the aim of inhibiting cell proliferation and promoting apoptosis in non-melanoma skin cancers.
  • [MeSH-major] Bowen's Disease / metabolism. Sirtuins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Apoptosis / physiology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Proliferation. Gene Expression Regulation, Neoplastic. Humans. Keratosis / metabolism. Keratosis / pathology. Sirtuin 1


52. Mohammadi A, Rosa M, Rhatigan R: Eyelid basal cell carcinoma associated with solitary neurofibroma. J Cutan Pathol; 2010 Jun;37(6):707-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma associated with solitary neurofibroma.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Eyelid Neoplasms / complications. Neurofibroma / complications

  • Genetic Alliance. consumer health - Neurofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614728.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  •  go-up   go-down


53. Yamane GK: Cancer incidence in the U.S. Air Force: 1989-2002. Aviat Space Environ Med; 2006 Aug;77(8):789-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in the U.S. Air Force: 1989-2002.
  • BACKGROUND: Cancer incidence in U.S.
  • METHODS: Standardized incidence ratios (SIRs) for invasive cancer in AFAD personnel during 1989-2002 were determined using U.S. national incidence rates as the reference.
  • Cutaneous squamous and basal cell carcinomas (CAs) were excluded.
  • RESULTS: There were 2750 cases: 1986 in men and 764 in women.
  • Among men, the 10 most frequent cancers (77.6% of total) were, in descending order: melanoma; testicular CA; prostate CA; non-Hodgkin lymphoma; follicular/papillary thyroid CA; Hodgkin's Disease; colorectal CA; brain neuroepithelial CA; and (tied) bladder CA and oral squamous cell CA.
  • Among women, the 10 most frequent cancers (88.1% of total) were, in descending order: breast CA; cervical CA; follicular/papillary thyroid CA; melanoma; Hodgkin's Disease; colorectal CA;.
  • (tied) non-Hodgkin lymphoma and ovarian epithelial CA; vulvar CA; and (tied) brain neuroepithelial CA and oral squamous cell CA.
  • Compared with the U.S. population, cancer type-specific SIRs were significantly increased for cervical CA, prostate CA, and vulvar CA (range, 1.44-3.54).
  • SIRs were significantly decreased for bladder CA (men), brain neuroepithelial CA, colorectal CA (men), Hodgkin's Disease (men), non-Hodgkin lymphoma, oral squamous cell CA (men), and testicular CA (range, 0.31-0.68).
  • CONCLUSIONS: The cancer experience of the AFAD population differs substantially from that of the U.S. population.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909871.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Housman TS, Berg D, Most SP, Odland PB, Stoddard E: Repair of the philtrum: an illustrative case series. J Cutan Med Surg; 2008 Nov-Dec;12(6):288-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repair of the philtrum: an illustrative case series.
  • OBJECTIVE: This case series describes reconstructive approaches to six philtral defects after Mohs micrographic surgery.
  • Reconstructive approaches including advancement flaps, full-thickness skin grafts, and second-intention healing are illustrated.
  • CONCLUSION: The reasonable success of full-thickness skin grafts demonstrated here provides an additional approach to philtral repairs, especially when combined with traditional advancement flaps.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Lip / surgery. Lip Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery. Skin Transplantation. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TRIAMCINOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317951.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 1ZK20VI6TY / Triamcinolone
  •  go-up   go-down


55. Fan XS, Wu HY, Yu HP, Zhou Q, Zhang YF, Huang Q: Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. Int J Colorectal Dis; 2010 May;25(5):583-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUNDS AND AIMS: Lgr5 is a member of the G protein receptor super-family and was shown recently to be a stem cell marker for cells with intestinal differentiation.
  • Its over-expression has been demonstrated in hepatocellular, basal cell carcinoma, and ovarian cancers but the underlying mechanisms are poorly understood.
  • METHODS: The study was carried out on a tissue microarray that consisted of 102 colorectal carcinomas (CRC; M:F = 55:47), 18 colon adenoma, and 12 colon normal mucosa cases.
  • Subsequently, expression of Lgr5 in tissue sections of tumor centre and invasive margins of 21 cases of CRC certified to be immunoreactive of Lgr5 in TMA were evaluated and possible differences of Lgr5 expression between them were analyzed.
  • RESULTS: Lgr5 immunoreactivity was observed only in single cells in the base of normal colon mucosal crypts but high in 28% (five out of 18) adenomas, and significantly higher in 54% (55/102, p = 0.016) CRC cases.
  • In normal mucosa, adenoma, and CRC, beta-catenin expression was seen in 25% (three out of 12), 27% (five out of 18), and 81% (83/102) cases, respectively, in contrast to 0, 0, and 40% (41/102) for p53 expression, respectively.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anat. 2008 Jul;213(1):52-8 [18638070.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):379-83 [9697701.001]
  • [Cites] Front Biosci. 2008 May 01;13:3352-63 [18508437.001]
  • [Cites] Mol Endocrinol. 1998 Dec;12(12):1830-45 [9849958.001]
  • [Cites] Hepatology. 2003 Mar;37(3):528-33 [12601349.001]
  • [Cites] Mol Endocrinol. 2000 Feb;14(2):272-84 [10674399.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17 ):6027-32 [15837931.001]
  • [Cites] Science. 2004 Mar 12;303(5664):1684-6 [15017003.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2862-70 [18539965.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Int J Surg Pathol. 2007 Jan;15(1):38-52 [17172496.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):363-71 [16489634.001]
  • [Cites] Transl Res. 2008 Jan;151(1):10-6 [18061123.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):835-43 [18688030.001]
  • [Cites] Cell Signal. 2007 Dec;19(12):2428-33 [17651940.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] ScientificWorldJournal. 2008 Nov 23;8:1168-76 [19030762.001]
  • [Cites] Nat Genet. 2004 Oct;36(10 ):1117-21 [15378062.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2828-38 [18539961.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):387-98 [18432252.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4042-5 [17634527.001]
  • [Cites] Annu Rev Physiol. 2009;71:241-60 [18808327.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:351-6 [19478326.001]
  • [Cites] Adv Pathobiol. 1977;(6):141-52 [899956.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):9736-43 [15509778.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):419-26 [16575208.001]
  • [Cites] Pathobiology. 2006;73(5):213-23 [17314492.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):755-68 [18784658.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1904-9 [15790842.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3304-13 [18451157.001]
  • (PMID = 20195621.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / LGR5 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
  •  go-up   go-down


56. Hanavadi S, Monypenny IJ, Mansel RE: Is mammography overused in male patients? Breast; 2006 Feb;15(1):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is no agreed protocol for the use of mammography in evaluating the male breast.
  • In order to define the role of mammography in men, we carried out a retrospective analysis of all male patients referred to the breast clinic with a history of breast lump between January 2001 and December 2003.
  • The impact of mammography in the evaluation of male breast cancer cases was studied.
  • A total of 220 male patients were referred to the breast clinic during this period.
  • Of these, 134 men had a mammographic examination, with majority (96%) being performed prior to their consultation with the breast clinician as per the clinic protocol.
  • There were 4 cases of breast cancer diagnosed during this period.
  • Breast cancer was suspected in all patients on clinical examination and was confirmed by biopsy.
  • Breast cancer in men can be suspected on clinical examination in the majority of cases.
  • One should consider imaging only those with clinically suspicious breast lumps to avoid unnecessary imaging particularly in young male patients.
  • [MeSH-major] Breast Neoplasms, Male / radiography. Mammography / utilization
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy. Breast Diseases / radiography. Child. Diagnosis, Differential. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473746.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


57. Khanmohammadi M, Nasiri R, Ghasemi K, Samani S, Bagheri Garmarudi A: Diagnosis of basal cell carcinoma by infrared spectroscopy of whole blood samples applying soft independent modeling class analogy. J Cancer Res Clin Oncol; 2007 Dec;133(12):1001-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of basal cell carcinoma by infrared spectroscopy of whole blood samples applying soft independent modeling class analogy.
  • Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy was applied to discriminate the blood samples obtained from healthy people and those with basal cell carcinoma, demonstrating high accuracy while soft independent modeling class analogy (SIMCA) chemometric technique is benefited.
  • It was aimed to classify the normal case and cancer case blood samples through the use of ATR-FTIR spectroscopy as a rapid method while the sample preparation is so easy in comparison with the common pathologic methods.
  • A total of 72 blood samples, including 32 cancer and 40 normal cases, were analyzed in 1,800-900 cm(-1) spectral region.
  • [MeSH-major] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / blood. Skin Neoplasms / diagnosis. Spectroscopy, Fourier Transform Infrared

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Cancer Res Clin Oncol. 2007 Dec;133(12):1023
  • [Cites] Am J Pathol. 1992 Jul;141(1):25-9 [1632467.001]
  • [Cites] Talanta. 1999 Jun;49(1):189-97 [18967589.001]
  • [Cites] J Invest Dermatol. 1999 Jun;112(6):951-6 [10383744.001]
  • [Cites] Arch Dermatol Res. 2000 Aug;292(8):379-83 [10994771.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):747-52 [9044855.001]
  • [Cites] Leuk Res. 1984;8(3):483-9 [6748732.001]
  • [Cites] Biopolymers. 2004 Dec 5;75(5):384-92 [15457432.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):762-5 [8428355.001]
  • [Cites] Sci Total Environ. 1997 Nov 14;207(1):29-42 [9397597.001]
  • [Cites] Anticancer Res. 1989 Jan-Feb;9(1):65-70 [2468307.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1998 Feb;44(1):189-202 [9551650.001]
  • [Cites] Cancer Detect Prev. 2004;28(1):32-6 [15041075.001]
  • [Cites] Appl Opt. 1999 May 1;38(13):2916-26 [18319874.001]
  • [Cites] J Biomed Opt. 2002 Apr;7(2):248-54 [11966311.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):397-404 [17882650.001]
  • [Cites] Hunan Yi Ke Da Xue Xue Bao. 1999;24(2):179-80 [11938785.001]
  • [Cites] J Biomed Opt. 2006 Nov-Dec;11(6):064026 [17212549.001]
  • [Cites] IARC Sci Publ. 1997;(142):291-301 [9354928.001]
  • [Cites] Histopathology. 1992 Dec;21(6):579-81 [1468757.001]
  • [Cites] IARC Sci Publ. 2001;154:81-91 [11220671.001]
  • [Cites] Rheumatol Int. 1995;15(4):159-65 [8835298.001]
  • [Cites] Ann Clin Biochem. 1998 Sep;35 ( Pt 5):624-32 [9768328.001]
  • [Cites] J Biol Chem. 1949 Mar;178(1):335-43 [18112117.001]
  • [Cites] Br J Dermatol. 2006 Apr;154(4):586-93 [16536798.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15327-32 [9860968.001]
  • [Cites] Pathol Oncol Res. 2000;6(4):272-4 [11173659.001]
  • (PMID = 17671793.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Essers BA, Dirksen CD, Prins MH, Neumann HA: Assessing the public's preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands. Dermatol Surg; 2010 Dec;36(12):1950-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the public's preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands.
  • BACKGROUND: Basal cell carcinoma (BCC) is a slowly growing nonmelanoma type of skin cancer that often is located on the face.
  • Different therapies are available to treat BCC, of which surgical excision (SE) and Mohs micrographic surgery (MMS) are the most frequently used surgical procedures.
  • METHODS: A discrete-choice experiment (DCE) was conducted among members of the general public to examine which attributes of a surgical treatment for primary BCC are valued as important.
  • RESULTS: Respondents (N=312) preferred a treatment with a lower recurrence rate, shorter surgery time, shorter travelling time, shorter waiting time, no risk for re-excision, and lower cost.
  • CONCLUSIONS: Results from this DCE indicate that, when outcome and process attributes are considered from a societal perspective, MMS is preferred over SE for primary BCC.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery. Public Opinion. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / psychology. Netherlands. Reoperation / psychology. Risk. Surveys and Questionnaires. Time Factors. Travel. Waiting Lists

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 by the American Society for Dermatologic Surgery, Inc.
  • (PMID = 21070461.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Mentzel T, Kutzner H, Requena L, Hartmann A: [Skin tumors as marker lesions for tumor syndromes]. Pathologe; 2010 Oct;31(6):489-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin tumors as marker lesions for tumor syndromes].
  • A number of hereditary tumor syndromes are associated with characteristic dermal neoplasms and knowledge and early diagnosis of these lesions may facilitate the diagnostic of the underlying syndrome.
  • These syndromes include Muir-Torre syndrome, associated with cystic sebaceomas, Cowden syndrome, associated with multiple tricholemmomas, Carney complex associated with multiple superficial angiomyxomas, Birt-Hogg-Dubé syndrome associated with multiple fibrofolliculomas, tuberous sclerosis associated with multiple facial angiofibromas and so-called Koenen tumors, patients with renal cell cancer associated with pilar leiomyomatosis and uterine leiomyomas, Gardner syndrome associated with Gardner fibromas and nevoid basal cell carcinoma associated with multiple basal cell carcinomas in young patients.
  • [MeSH-major] Biomarkers, Tumor. Carney Complex / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Angiofibroma / pathology. Basal Cell Nevus Syndrome / pathology. Birt-Hogg-Dube Syndrome / pathology. Carcinoma, Basal Cell / pathology. Epidermis / pathology. Hamartoma Syndrome, Multiple / pathology. Humans. Kidney Neoplasms / pathology. Leiomyoma / pathology. Male. Muir-Torre Syndrome / pathology. Myxoma / pathology. Syndrome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dermatopathol. 1999 Oct;21(5):405-13 [10535567.001]
  • [Cites] J Cutan Pathol. 2005 Jul;32(6):424-8 [15953376.001]
  • [Cites] Am J Dermatopathol. 2006 Feb;28(1):1-8 [16456317.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):406-10 [11865300.001]
  • [Cites] J Med Genet. 2004 Jul;41(7):567-72 [15235030.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):910-7 [10435560.001]
  • [Cites] Arch Dermatol. 1977 Dec;113(12):1674-7 [596896.001]
  • [Cites] Science. 2004 Jun 18;304(5678):1755-9 [15205520.001]
  • [Cites] Am J Dermatopathol. 1992 Apr;14(2):107-4 [1373583.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Medicine (Baltimore). 1985 Jul;64(4):270-83 [4010501.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):501-8 [15992699.001]
  • [Cites] Eur J Dermatol. 2009 Nov-Dec;19(6):545-51 [19939761.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):645-51 [11342777.001]
  • [Cites] Am J Hum Genet. 1998 Jul;63(1):63-70 [9634524.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):410-6 [17325483.001]
  • [Cites] Ann Intern Med. 1963 Jan;58:136-42 [13931122.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Int J Gynecol Pathol. 1997 Oct;16(4):325-34 [9421071.001]
  • [Cites] Am J Surg Pathol. 1988 Jul;12(7):519-30 [3389450.001]
  • [Cites] Hautarzt. 2004 Oct;55(10):942-51 [15349693.001]
  • [Cites] J Med Genet. 2004 May;41(5):323-6 [15121767.001]
  • [Cites] Histopathology. 2010 Jan;56(1):133-47 [20055911.001]
  • [Cites] Histopathology. 2010 Jan;56(2):251-62 [20102404.001]
  • (PMID = 20960199.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Cöloğlu H, Koçer U, Oruç M, Sahin B, Ozdemir R: Axial bilobed superficial temporal artery island flap (tulip flap): reconstruction of combined defects of the lateral canthus including the lower and upper eyelids. Plast Reconstr Surg; 2007 Jun;119(7):2080-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Eyelids / surgery. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Surgical Flaps / blood supply
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / surgery. Female. Humans. Male. Microsurgery. Middle Aged. Nevus, Pigmented / congenital. Nevus, Pigmented / surgery. Temporal Arteries

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Plast Reconstr Surg. 2008 May;121(5):1857-8 [18454017.001]
  • (PMID = 17519704.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Marasà L, Marasà S, Sciancalepore G: Collagen IV, laminin, fibronectin, vitronectin. Comparative study in basal cell carcinoma. Correlation between basement membrane molecules expression and invasive potential. G Ital Dermatol Venereol; 2008 Jun;143(3):169-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen IV, laminin, fibronectin, vitronectin. Comparative study in basal cell carcinoma. Correlation between basement membrane molecules expression and invasive potential.
  • AIM: Basal cell carcinoma (BCC) is a malignant carcinoma arising by cells of epidermal basal layer and adnexal epithelium.
  • METHODS: Particularly formalin-fixed, paraffin-embedded tissue from 40 cases of BCC, 20 recurring and 20 not recurring, had been studied, with immunohistochemical techniques to value the distribution of intrinsic and extrinsic components of basal membrane.
  • RESULTS: The immunohistochemical examination showed collagen IV and laminin continuous positivity in peripheral cells, seating around neoplastic nests of 62.5% not recurring BCC.
  • The same antigens exhibited discontinuous positivity in cells with non distinguished borders, seating around nests of 85% micronodular recurring BCC.
  • Fibronectin in fact appeared hyper-expressed in peritumoral stroma of 80% recurring BCC, vitronectin appeared less expressed than normally in peritumoral stroma of 95% recurring BCC.
  • CONCLUSION: A correlation between basal membrane's break and carcinoma's recurrence has been noticed.
  • This shows the utility of other prognostic factors helping the valuation of malignant progression.
  • [MeSH-major] Basement Membrane / chemistry. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Collagen Type IV / analysis. Fibronectins / analysis. Laminin / analysis. Skin Neoplasms / chemistry. Skin Neoplasms / pathology. Vitronectin / analysis
  • [MeSH-minor] Humans. Immunohistochemistry. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833058.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Fibronectins; 0 / Laminin; 0 / Vitronectin
  •  go-up   go-down


62. Del Rosso JQ: The treatment of viral infections and nonmelanoma skin cancers. Cutis; 2007 Apr;79(4 Suppl):29-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of viral infections and nonmelanoma skin cancers.
  • Immunomodulatory therapy, which functions to upregulate immune response, may be directed against a variety of disease states, including viral infections and skin malignancies.
  • Topical imiquimod has been studied for a variety of different disorders including human papillomavirus infection, molluscum contagiosum, actinic keratosis (AK), squamous cell carcinoma (SCC) in situ, superficial basal cell carcinoma (sBCC), nodular basal cell carcinoma (nBCC), and lentigo maligna.
  • Case reports also have demonstrated use for select cases of extramammary Paget disease.
  • This article focuses on therapies designed to augment immune response to treat viral infections and nonmelanoma skin cancers and reviews clinical applications, efficacy, recommended treatment regimens, monitoring of response, and avoidance of pitfalls associated with the use of topical imiquimod.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Interferons / therapeutic use. Skin Diseases, Viral / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508493.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  • [Number-of-references] 53
  •  go-up   go-down


63. Belisle A, Gautier MS, Ghozali F, Plantier F, Wechsler J: A collision tumor involving Basal cell carcinoma and lentigo maligna melanoma. Am J Dermatopathol; 2005 Aug;27(4):319-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A collision tumor involving Basal cell carcinoma and lentigo maligna melanoma.
  • Basal cell carcinomas (BCC) are known to co-exist with other cutaneous lesions, but the collision of BCC with malignant melanoma is rare.
  • We report on the case of an 82-year-old woman with a translucent papule set on a beige-brown plaque on the right side of the nose.
  • Histologic examination showed lesions of lentigo maligna melanoma (LMM) in situ and invasive melanoma involving nests of BCC that invaded the dermis.
  • Immunohistochemical studies with S100 protein, HMB-45, and Melan-A antibodies showed the melanocytic component in the epidermis and dense clusters of "atypical" melanocytes in the dermal nests of BCC.
  • On examination of the biopsy specimen, melanoma was still in situ because it was limited to the nests of BCC and not detectable between dermal collagen bundles.
  • However, the re-excision of the lesion showed residual BCC and invasive LMM, level II, measuring 0.2 mm in thickness.
  • The diagnosis, pathogenesis, and prognosis of this collision tumor are discussed.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratosis / pathology. Melanoma / pathology. Prognosis

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121053.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Yoo YS, Woo HY, Choi JH, Cho KR, Oh YT, Heo G: Balloon catheter assisted excision of benign cervical cyst. Auris Nasus Larynx; 2010 Aug;37(4):504-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Benign cystic masses that develop in the neck are easily excised with a wide skin incision.
  • METHODS: Two cases with a branchial cleft cyst (BCC) were removed using this method without recurrence.
  • The surgical technique includes a skin incision above the cyst, and fine dissection to expose the cyst wall.
  • The final pathological diagnosis was BCC in the two cases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20053514.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 10
  •  go-up   go-down


65. Man I, Crombie IK, Dawe RS, Ibbotson SH, Ferguson J: The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol; 2005 Apr;152(4):755-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To determine the skin cancer incidence in a population treated with TL-01 phototherapy.
  • Patients with malignant melanoma (MM), squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) were identified by record linkage with the Scottish Cancer Registry.
  • Ten patients developed BCC compared with an expected 4.7 in the Scottish population [standardized rate ratio 213 (95% confidence interval 102-391); P < 0.05].
  • CONCLUSIONS: A small but significant increase of BCC was detected in the TL-01 group.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Neoplasms, Radiation-Induced / etiology. Skin Neoplasms / etiology. Ultraviolet Therapy / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2006 Mar;154(3):566-7 [16445801.001]
  • (PMID = 15840109.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J: UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways. Br J Dermatol; 2009 Nov;161 Suppl 3:107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways.
  • The incidence of nonmelanoma skin cancer including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) has dramatically increased in the last decades, and chronic sun exposure was identified as a main etiologic agent.
  • As mutations caused by UV may lead to skin cancer due to oncogene activation and tumor suppressor gene inactivation, efficient safeguard mechanisms have been developed during evolution.
  • The keratinocyte apoptotic machinery in response to UV consists of both intrinsic/mitochondrial and extrinsic/death receptor-mediated cell-death pathways, which are particularly regulated by mitogen-activated protein kinases (MAPKs, JNK and p38) and the tumor-suppressor protein p53.
  • For development of skin cancer, it appears that critical steps in apoptosis control are dysregulated leading to resistance both to death ligand-mediated and intrinsic proapoptotic pathways.
  • The final unravelling of apoptosis regulation in epithelial skin cancer may allow the development of new targeted therapeutic strategies.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / etiology. DNA Damage. Signal Transduction / radiation effects. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / pathology. Humans. Mitochondria / genetics. Mitochondria / pathology. Mitochondria / radiation effects. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / genetics. Neoplasms, Radiation-Induced / pathology. Skin Neoplasms / etiology. Skin Neoplasms / genetics. Skin Neoplasms / pathology. TNF-Related Apoptosis-Inducing Ligand / metabolism


67. Moehrle M, Breuninger H, Schippert W, Häfner HM: Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study. Dermatol Surg; 2010 Mar;36(3):428-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Mohs Surgery. Neoadjuvant Therapy. Nose Neoplasms / drug therapy. Nose Neoplasms / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Dermatol Surg. 2009 Jan;35(1):24-9 [19018814.001]
  • (PMID = 20402949.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


68. Kurokawa I, Senba Y, Nishimura K, Habe K, Hakamada A, Isoda K, Yamanaka K, Mizutani H, Tsubura A: Cytokeratin expression in trichilemmal carcinoma suggests differentiation towards follicular infundibulum. In Vivo; 2006 Sep-Oct;20(5):583-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin expression in trichilemmal carcinoma suggests differentiation towards follicular infundibulum.
  • An immunohistochemical study of cytokeratins (CK) in a case of trichilemmal carcinoma (TLC).
  • Trichilemmal carcinoma (TLC) is a rare cutaneous tumor, and is considered as a malignant counterpart of trichilemmoma.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Aged. Cell Differentiation. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091763.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


69. Xie J: Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochim Biophys Sin (Shanghai); 2008 Jul;40(7):670-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of hedgehog signaling antagonists for cancer therapy.
  • The hedgehog (Hh) pathway, initially discovered in Drosophila by two Nobel laureates, Dr.
  • Eric Wieschaus and Dr.
  • Christiane Nusslein-Volhard, is a major regulator for cell differentiation, tissue polarity and cell proliferation.
  • Studies from many laboratories, including ours, reveal activation of this pathway in most basal cell carcinomas and in approximately 30% of extracutaneous human cancers, including medulloblastomas, gastrointestinal, lung, breast and prostate cancers.
  • Even more exciting is the discovery and synthesis of specific signaling antagonists for the Hh pathway, which have significant clinical implications in novel cancer therapeutics.
  • This review discusses the major advances in the current understanding of Hh signaling activation in different types of human cancers, the molecular basis of Hh signaling activation, the major antagonists for Hh signaling inhibition and their potential clinical application in human cancer therapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3161-73 [17114586.001]
  • [Cites] PLoS Biol. 2006 Jul;4(8):e232 [16895439.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1415-23 [17115028.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6442-7 [17452975.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):961-4 [18281468.001]
  • [Cites] Adv Exp Med Biol. 2008;624:241-51 [18348461.001]
  • [Cites] Curr Oncol Rep. 2008 Mar;10(2):107-13 [18377823.001]
  • [Cites] Nature. 2004 Dec 23;432(7020):1045-50 [15616566.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7186-9 [12499255.001]
  • [Cites] Dev Biol. 2003 Feb 1;254(1):1-18 [12606278.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21 [12679522.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):799-812 [12791266.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Nature. 2003 Nov 6;426(6962):83-7 [14603322.001]
  • [Cites] Dev Cell. 2004 Jun;6(6):801-13 [15177029.001]
  • [Cites] J Biol. 2002 Nov 6;1(2):10 [12437772.001]
  • [Cites] Endocrinology. 2004 Aug;145(8):3961-70 [15132968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10833-8 [15249678.001]
  • [Cites] BMC Cancer. 2004 Aug 4;4:43 [15294024.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):622-6 [8757131.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Curr Biol. 1996 Mar 1;6(3):298-304 [8805249.001]
  • [Cites] Science. 1996 Oct 11;274(5285):255-9 [8824192.001]
  • [Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(1):41-5 [10537006.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):312-9 [10559945.001]
  • [Cites] Development. 2000 Apr;127(8):1593-605 [10725236.001]
  • [Cites] Nature. 2000 Jul 6;406(6791):86-90 [10894547.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21856-61 [10806213.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):757-62 [11257109.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):555-8 [11340611.001]
  • [Cites] Cell. 2001 Jun 15;105(6):781-92 [11440720.001]
  • [Cites] Nature. 2001 Jul 12;412(6843):194-8 [11449277.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9255-9 [11481486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5442-7 [11960000.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):306-10 [12068298.001]
  • [Cites] Curr Biol. 2002 Jun 25;12(12):983-95 [12123571.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:47-65 [12142354.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6 [12391318.001]
  • [Cites] Nature. 2002 Oct 31;419(6910):929-34 [12410312.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):17900-7 [15598741.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):45-64 [15580285.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):43-51 [15656799.001]
  • [Cites] Mol Carcinog. 2005 Apr;42(4):183-92 [15754313.001]
  • [Cites] Curr Top Med Chem. 2005;5(2):147-57 [15853643.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):7042-53 [16055716.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):7054-68 [16055717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11325-30 [16061793.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):728-33 [15970691.001]
  • [Cites] Differentiation. 2005 Oct;73(8):397-405 [16316410.001]
  • [Cites] Development. 2006 Jan;133(1):3-14 [16339192.001]
  • [Cites] Genes Dev. 2006 Jan 1;20(1):22-7 [16357211.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):9-12 [16293631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):33-8 [16371461.001]
  • [Cites] Genes Dev. 2006 Feb 1;20(3):276-81 [16421275.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):177-86 [16459297.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Cancer Biol Ther. 2006 Jan;5(1):111-7 [16397407.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):748-57 [16339184.001]
  • [Cites] Pancreas. 2006 Mar;32(2):119-29 [16552330.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):331-8 [16556007.001]
  • [Cites] Mol Cell Biol. 2006 May;26(9):3365-77 [16611981.001]
  • [Cites] Cell. 2006 Apr 21;125(2):343-57 [16630821.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3764-72 [16648472.001]
  • [Cites] Cell. 2006 May 5;125(3):439-42 [16678091.001]
  • [Cites] Dev Cell. 2006 May;10(5):657-65 [16647303.001]
  • [Cites] Dev Cell. 2006 May;10(5):647-56 [16647304.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1334-40 [16501253.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):3965-9 [16810741.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):14-29 [16831586.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6964-71 [16849540.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):674-83 [16855373.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6283-98 [16880536.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(17):6609-22 [16914743.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Nat Rev Genet. 2006 Nov;7(11):841-50 [17047684.001]
  • [Cites] Gene Ther. 2006 Nov;13(22):1587-94 [16826192.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):369-73 [17086203.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Development. 1997 Apr;124(7):1313-22 [9118802.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1798-803 [9581815.001]
  • [Cites] Nat Med. 1998 May;4(5):619-22 [9585239.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Nature. 1998 Jul 2;394(6688):85-8 [9665133.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):54-7 [9731531.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):833-6 [9989836.001]
  • [Cites] Nature. 1999 Feb 18;397(6720):617-21 [10050855.001]
  • [Cites] Genes Dev. 1999 Aug 15;13(16):2072-86 [10465785.001]
  • [Cites] Genes Dev. 1999 Sep 15;13(18):2375-87 [10500095.001]
  • [Cites] Development. 1999 Nov;126(21):4873-84 [10518503.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1018-21 [16136078.001]
  • [Cites] PLoS Genet. 2005 Oct;1(4):e53 [16254602.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):378-89 [16229832.001]
  • [Cites] Oncology. 2006;70(5):378-89 [17179732.001]
  • [Cites] Mol Cancer. 2006;5:74 [17173689.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1389-98 [17332280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53 [17360475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5103-8 [17372229.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1010-7 [17373734.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1051-5 [17390043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] Pancreas. 2007 Apr;34(3):340-6 [17414057.001]
  • [Cites] Genes Dev. 2007 May 15;21(10):1231-43 [17504940.001]
  • [Cites] Genes Dev. 2007 May 15;21(10):1244-57 [17504941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60 [17494766.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1575-84 [17525797.001]
  • [Cites] Cell Cycle. 2006 Nov 1;5(21):2457-63 [17102630.001]
  • [Cites] Nat Med. 2007 Aug;13(8):944-51 [17632527.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5752-61 [17353902.001]
  • [Cites] Breast Cancer Res Treat. 2007 Oct;105(2):139-55 [17295047.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Nature. 1980 Oct 30;287(5785):795-801 [6776413.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Nature. 1988 Mar 24;332(6162):371-4 [2832761.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3104-13 [2850480.001]
  • [Cites] Mol Cell Biol. 1990 Feb;10(2):634-42 [2105456.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Am J Med Genet. 1993 May 15;46(3):317-34 [8488879.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1401-16 [8269518.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1417-30 [7916661.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1431-44 [8269519.001]
  • [Cites] Cell. 1994 Feb 25;76(4):761-75 [8124714.001]
  • [Cites] Science. 1994 Dec 2;266(5190):1528-37 [7985023.001]
  • [Cites] Nature. 1995 Mar 23;374(6520):363-6 [7885476.001]
  • [Cites] Development. 1994 Nov;120(11):3339-53 [7720571.001]
  • [Cites] Genes Dev. 1996 Feb 1;10(3):301-12 [8595881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1571-6 [8643673.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • (PMID = 18604459.001).
  • [ISSN] 1745-7270
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094160; United States / NCI NIH HHS / CA / R01 CA094160-06A2; United States / NCI NIH HHS / CA / CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins
  • [Number-of-references] 149
  • [Other-IDs] NLM/ NIHMS56053; NLM/ PMC2515624
  •  go-up   go-down


70. Taneja S, Evans AJ, Rakha EA, Green AR, Ball G, Ellis IO: The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. Clin Radiol; 2008 Nov;63(11):1228-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mammographic correlations of a new immunohistochemical classification of invasive breast cancer.
  • AIM: Recent protein expression profiling of breast cancer has identified specific subtypes with clinical, biological, and therapeutic implications.
  • The aim of this study was to identify the mammographic correlates of these novel molecular classes of invasive breast cancer.
  • MATERIALS AND METHODS: The mammographic findings of 415 patients with operable breast cancer were correlated with the previously described protein expression classes identified by our group using immunohistochemical (IHC) assessment of a large series of breast cancer cases prepared as tissue microarrays (TMAs).
  • Twenty-five proteins of known relevance in breast cancer were assessed, including hormone receptors, HER-2 status, basal and luminal markers, p53 expression, and E-cadherin.
  • Groups characterized by HER-2 overexpression, basal characteristics, and E-cadherin positivity had a significantly higher proportion of ill-defined masses.
  • CONCLUSION: The mammographic features of breast cancer show significant correlation with molecular classes of invasive breast cancer identified by protein expression IHC analysis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Cadherins / metabolism. Female. Humans. Lymphatic Metastasis. Mammography. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism


71. Rollison DE, Giuliano AR, Sellers TA, Laronga C, Sweeney C, Risendal B, Baumgartner KB, Byers T, Slattery ML: Population-based case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic White women living in US southwestern states. Am J Epidemiol; 2008 Feb 15;167(4):447-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic White women living in US southwestern states.
  • Diabetes mellitus has been associated with breast cancer, although no studies appear to have adequately assessed the association in Hispanic women, a population with a high prevalence of diabetes.
  • The authors investigated this association in a population-based case-control study of Hispanic and non-Hispanic White women living in the southwestern United States.
  • Breast cancer cases diagnosed in 1999-2004 were identified through state cancer registries (1,526 non-Hispanic Whites, 798 Hispanics).
  • Having any type of diabetes was not associated with breast cancer overall (odds ratio = 0.94, 95% confidence interval: 0.78, 1.12).
  • Type 2 diabetes was observed among 19% of Hispanics and 9% of non-Hispanic Whites but was not associated with breast cancer in either group.
  • Gestational diabetes was inversely associated with breast cancer in both ethnic groups, especially when first diagnosed at age < or =35 years (odds ratio = 0.54, 95% confidence interval: 0.37, 0.79).
  • In this study, diabetes was not associated with breast cancer overall, although the inverse association with gestational diabetes warrants further investigation.

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes Care. 2003 Apr;26(4):1047-51 [12663571.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):129-35 [17476589.001]
  • [Cites] Int J Epidemiol. 1999 Oct;28(5):816-23 [10597976.001]
  • [Cites] J Natl Cancer Inst. 1970 Mar;44(3):673-86 [11515436.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):875-80 [11808705.001]
  • [Cites] Am J Epidemiol. 2002 Aug 15;156(4):349-52 [12181105.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):149-55 [14692035.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):267-75 [15090721.001]
  • [Cites] Diabetes Care. 2004 May;27(5):1194-9 [15111544.001]
  • [Cites] Am J Epidemiol. 2004 Jun 15;159(12):1160-7 [15191933.001]
  • [Cites] Int J Cancer. 1974 Aug 15;14(2):153-60 [4378317.001]
  • [Cites] J Chronic Dis. 1982;35(1):13-9 [7068798.001]
  • [Cites] J Chronic Dis. 1985;38(5):435-41 [3998058.001]
  • [Cites] Diabetes Metab Rev. 1990 Feb;6(1):29-45 [2192854.001]
  • [Cites] Eur J Cancer. 1990;26(7):781-5 [2145895.001]
  • [Cites] Int J Gynaecol Obstet. 1991 May;35(1):13-8 [1680070.001]
  • [Cites] Diabetes Care. 1991 Jul;14(7):695-705 [1914821.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):965-73 [1595695.001]
  • [Cites] Epidemiology. 1994 Jan;5(1):102-8 [8117767.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):807-11 [8634649.001]
  • [Cites] Prev Med. 1997 Jan-Feb;26(1):144-53 [9010910.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):360-3 [9139868.001]
  • [Cites] Br J Cancer. 1997;75(11):1699-703 [9184190.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5 [9308706.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] Diabetes. 1998 Aug;47(8):1302-10 [9703332.001]
  • [Cites] Am J Epidemiol. 1998 Oct 1;148(7):683-92 [9778175.001]
  • [Cites] Epidemiology. 1998 Nov;9(6):641-7 [9799175.001]
  • [Cites] J Intern Med. 1997 Jun;241(6):471-5 [10497622.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):194-202 [15644546.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):439-48 [15770008.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2070-5 [15886700.001]
  • [Cites] Diabetes Care. 2006 Jun;29(6):1263-8 [16732006.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):253-9 [16839219.001]
  • [Cites] Breast Cancer Res Treat. 2006 Aug;98(3):349-56 [16541321.001]
  • [Cites] Arch Intern Med. 2006 Sep 25;166(17):1871-7 [17000944.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):142-50 [17220343.001]
  • [Cites] Cancer Causes Control. 2007 Jun;18(5):505-15 [17437179.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):856-62 [17397032.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):85-101 [17080310.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1561-6 [17440036.001]
  • [Cites] Breast Cancer Res Treat. 2007 Aug;104(2):197-209 [17051426.001]
  • [Cites] Diabetes Care. 2003 Jun;26(6):1752-8 [12766105.001]
  • (PMID = 18033764.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078682-07; United States / NCI NIH HHS / CA / CA078682; United States / NCI NIH HHS / CA / R01 CA078552; United States / NCI NIH HHS / CA / R01 CA078762; United States / NCI NIH HHS / CA / CA078682-07; United States / NCI NIH HHS / CA / R01 CA078802; United States / NCI NIH HHS / CA / R01 CA078682; United States / NCI NIH HHS / CA / CA078552; United States / NCI NIH HHS / PC / N01-PC-67000; United States / NCI NIH HHS / CA / CA078762; United States / NCI NIH HHS / CA / CA078802
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS50878; NLM/ PMC2925515
  •  go-up   go-down


72. Centers for Disease Control and Prevention (CDC): Decline in breast cancer incidence--United States, 1999-2003. MMWR Morb Mortal Wkly Rep; 2007 Jun 8;56(22):549-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decline in breast cancer incidence--United States, 1999-2003.
  • Breast cancer is the most commonly diagnosed cancer among females in the United States.
  • The 2006 Annual Report to the Nation on the Status of Cancer described a stabilization in female breast cancer incidence rates during 2001-2003, ending increases that began in the 1980s, and a decline in the number of breast cancer cases diagnosed in 2003.
  • In addition, researchers who used 1990-2003 data from the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) program, representing approximately 14% of the U.S. population, reported a 7% decrease in invasive breast cancer rates from 2002 to 2003.
  • To further assess breast cancer annual incidence rates during 1999-2003, CDC analyzed data collected by CDC's National Program of Cancer Registries (NPCR) and the NCI SEER program.
  • The results of this analysis indicated that age-adjusted incidence rates for invasive breast cancer decreased each year during 1999-2003, with the greatest decrease (6.1%) occurring from 2002 to 2003; women aged > or = 50 years experienced a significant decrease during this period.
  • Rates of in situ (i.e., noninvasive) breast cancer increased each year during 1999-2002 and then decreased from 2002 to 2003; women aged 50-79 years experienced a significant decrease during this period.
  • [MeSH-major] Breast Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557070.001).
  • [ISSN] 1545-861X
  • [Journal-full-title] MMWR. Morbidity and mortality weekly report
  • [ISO-abbreviation] MMWR Morb. Mortal. Wkly. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Sellers TA, Jensen LE, Vierkant RA, Fredericksen ZS, Brandt KR, Giuliano AR, Pankratz VS, Cerhan JR, Vachon CM: Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study. Cancer Causes Control; 2007 Jun;18(5):505-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study.
  • Data from the Minnesota Breast Cancer Family Study cohort (n=6,130 women) were used to examine the association of type II diabetes with mammographic percent density and incident breast cancer (BC).
  • The first set of analyses evaluated diabetes (DM) as a risk factor for breast cancer.
  • A total of 403 women (6.6%) reported a diagnosis of type II diabetes and 333 women reported an incident breast cancer.
  • Women who reported type II diabetes had an age-adjusted relative risk (RR) for breast cancer of 1.44 (95% CI 0.89-2.32) compared to those who did not.
  • Breast cancer cases with diabetes did not have a significantly higher percent density than cases without diabetes.
  • Our findings suggest that breast cancer risk may be increased among women with type II diabetes, but that type II diabetes does not significantly influence mammographic breast density.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / epidemiology. Diabetes Mellitus, Type 2 / epidemiology. Mammography


74. Rajadhyaksha M: Confocal microscopy of skin cancers: translational advances toward clinical utility. Conf Proc IEEE Eng Med Biol Soc; 2009;2009:3231-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal microscopy of skin cancers: translational advances toward clinical utility.
  • Recent advances in translational research in and technology for confocal microscopy of skin cancers, toward clinical applications, are described.
  • Advances in translational research are in diagnosis of melanoma in vivo, pre-operative mapping of lentigo maligna melanoma margins to guide surgery and intra-operative imaging of residual basal cell carcinomas to guide shave-biopsy.
  • Advances in technology include mosaicing microscopy for detection of basal cell carcinomas in large areas of excised tissue, toward rapid pathology-at-the-bedside, and development of small, simple and low-cost line-scanning confocal microscopes for worldwide use in diverse primary healthcare settings.
  • [MeSH-major] Microscopy, Confocal / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Algorithms. Biopsy. Dermatology / instrumentation. Dermatology / methods. Dermoscopy / methods. Equipment Design. Humans. Hutchinson's Melanotic Freckle / diagnosis. Hutchinson's Melanotic Freckle / pathology. Melanoma / diagnosis. Melanoma / pathology. Reproducibility of Results. Sensitivity and Specificity. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Opt. 2007 Apr 1;46(10):1843-51 [17356629.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):644-58 [17630045.001]
  • [Cites] J Invest Dermatol. 2007 Dec;127(12):2759-65 [17657243.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):131-8 [18633444.001]
  • [Cites] J Microsc. 2009 Jan;233(1):149-59 [19196421.001]
  • [Cites] Opt Lett. 2006 Apr 1;31(7):942-4 [16599219.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034012 [19566305.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034050 [19566342.001]
  • [Cites] Arch Dermatol. 2001 Jul;137(7):923-9 [11453812.001]
  • [Cites] J Am Acad Dermatol. 2004 Dec;51(6):923-30 [15583584.001]
  • [Cites] Br J Dermatol. 2005 Nov;153(5):1031-6 [16225620.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1242-50 [19416248.001]
  • (PMID = 19964286.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01EB002715; United States / NCI NIH HHS / CA / R43 CA093106; United States / NIBIB NIH HHS / EB / R01EB006947; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / R44 CA093106; United States / NIBIB NIH HHS / EB / R01 EB006947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS582452; NLM/ PMC4040219
  •  go-up   go-down


75. Brailey LL, Davis T, Kolker SE, Murry TC, Thomas D, Bale AE, Ruhoy SM: Congenital linear unilateral basal cell nevus: a case report with patched gene molecular studies. J Cutan Pathol; 2007 Jan;34(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital linear unilateral basal cell nevus: a case report with patched gene molecular studies.
  • BACKGROUND: Linear unilateral basal cell nevus represents a linear collection of macules and papules histologically similar to basal cell carcinoma but with benign clinical behavior.
  • We describe a patient who initially presented at the age of 6 months with a unilateral linear basal cell nevus on the right flank.
  • The differential diagnosis included the nevoid basal cell carcinoma syndrome.
  • Constitutional PTCH mutations are causative of the nevoid basal cell carcinoma syndrome, and somatic PTCH mutations are found in the vast majority of basal cell carcinomas.
  • Somatic SMO mutations have also been found in some basal cell carcinomas.
  • RESULTS: Histologic examination revealed features initially indistinguishable from basal cell carcinoma.
  • CONCLUSION: Molecular examination indicates that the PTCH and SMO genes are not involved in the pathogenesis of the patients' congenital linear unilateral basal cell nevus.
  • Furthermore, we discuss the relationship between linear basal cell nevus and basaloid follicular hamartoma.
  • [MeSH-major] Nevus / genetics. Nevus / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology. Thigh
  • [MeSH-minor] DNA, Neoplasm. Diagnosis, Differential. Humans. Infant. Loss of Heterozygosity. Microsatellite Repeats. Mutation. Receptors, Cell Surface / genetics. Receptors, G-Protein-Coupled / genetics

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214858.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / patched receptors
  •  go-up   go-down


76. Tan E, Oakley A, Soyer HP, Haskett M, Marghoob A, Jameson M, Rademaker M: Interobserver variability of teledermoscopy: an international study. Br J Dermatol; 2010 Dec;163(6):1276-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Teledermoscopy is a rapidly developing field of dermatology with studies demonstrating excellent agreement with face-to-face diagnosis.
  • However, we are unaware of studies evaluating interobserver variability in diagnosis between dermatologists from different continents.
  • RESULTS: There was excellent agreement between four of five dermatologists (A-D) for lesions that were agreed upon as melanoma (κ = 0·81-0·97) and benign naevus (κ = 0·77-0·82).The fifth dermatologist (E) made a more frequent diagnosis of atypical naevus and melanoma than the others.
  • For nonmelanocytic lesions, there was moderate to very good agreement for seborrhoeic keratosis (κ = 0·64-0·80) and basal cell carcinoma (κ = 0·55-0·67), but poor agreement for invasive squamous cell carcinoma (SCC) (κ = 0·05-0·15).
  • There was good ability to distinguish malignant from benign lesions (κ = 0·57-0·93).
  • CONCLUSIONS: There was good agreement among dermatologists A-D but dermatologist E varied from the group with more frequent diagnosis of melanoma and atypical naevus.
  • [MeSH-major] Dermoscopy / methods. Remote Consultation / standards. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20795998.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Aulmann C, Seufert P, Sandherr M, Schlimok G, Schulze R, Oruzio D: [A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis]. Internist (Berl); 2007 Sep;48(9):1015-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis].
  • Low platelet counts and hyperfibrinolysis led to the diagnosis of recurrent breast cancer in this case.
  • A tumour disease with disturbed hemostasis caused by both plasmatic coagulation and thrombocytopenia has not yet been reported.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Fibrinolysis. Hemorrhagic Disorders / complications. Hemorrhagic Disorders / diagnosis. Thrombocytopenia / complications. Thrombocytopenia / diagnosis
  • [MeSH-minor] Aged. Female. Humans. Paraneoplastic Syndromes / complications. Paraneoplastic Syndromes / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1999 Aug;22(4):411-3 [10440202.001]
  • [Cites] South Med J. 2002 Nov;95(11):1335-7 [12540004.001]
  • [Cites] Thromb Haemost. 2001 Sep;86(3):828-33 [11583315.001]
  • [Cites] Am J Clin Pathol. 1979 Jan;71(1):10-6 [420161.001]
  • [Cites] Am J Clin Oncol. 2000 Feb;23(1):74-7 [10683084.001]
  • [Cites] Respir Med. 2004 Feb;98(2):93-8 [14971870.001]
  • [Cites] Semin Thromb Hemost. 1996;22(6):459-78 [9122711.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(10):555-9 [9393589.001]
  • [Cites] Jpn J Clin Oncol. 2001 Aug;31(8):388-94 [11574632.001]
  • [Cites] N Engl J Med. 1994 Nov 3;331(18):1207-11 [7935660.001]
  • [Cites] Blood Coagul Fibrinolysis. 2004 Jan;15(1):9-13 [15166937.001]
  • (PMID = 17704902.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Bikle DD, Oda Y, Xie Z: Vitamin D and skin cancer: a problem in gene regulation. J Steroid Biochem Mol Biol; 2005 Oct;97(1-2):83-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D and skin cancer: a problem in gene regulation.
  • The skin is the major source of Vitamin D(3) (cholecalciferol), and ultraviolet light (UV) is critical for its formation.
  • Keratinocytes, the major cell in the epidermis, can further convert Vitamin D(3) to its hormonal form, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] (calcitriol).
  • Skin cancers (squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and melanomas) are the most common cancers afflicting humans.
  • Skin cancers produce 1,25(OH)(2)D(3), contain ample amounts of the Vitamin D receptor (VDR), and respond to 1,25(OH)(2)D(3) with respect to induction of the 24-hydroxylase, but fail to differentiate in response to 1,25(OH)(2)D(3). Why not?
  • The explanation may lie in the overexpression of the DRIP complex, which by interfering with the normal transition from DRIP to SRC as coactivators of the VDR during differentiation, block the induction of genes required for 1,25(OH)(2)D(3)-induced differentiation.
  • [MeSH-major] Gene Expression Regulation / drug effects. Skin Neoplasms / genetics. Vitamin D / pharmacology
  • [MeSH-minor] Animals. Calcium / metabolism. Cell Differentiation / drug effects. Epidermis / cytology. Epidermis / metabolism. Epidermis / pathology. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039846.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / P01 AR39448; United States / PHS HHS / / R01 50023; United States / NIAMS NIH HHS / AR / R01 AR38386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  • [Number-of-references] 54
  •  go-up   go-down


79. Schön M, Kähne T, Gollnick H, Schön MP: Expression of gp130 in tumors and inflammatory disorders of the skin: formal proof of its identity as CD146 (MUC18, Mel-CAM). J Invest Dermatol; 2005 Aug;125(2):353-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of gp130 in tumors and inflammatory disorders of the skin: formal proof of its identity as CD146 (MUC18, Mel-CAM).
  • Two antibodies, BT14 and L101, detect a tumor-associated cell surface glycoprotein (gp130) whose properties in normal and diseased skin were assessed, and whose molecular identity was determined in this study.
  • In normal skin, gp130 was constitutively expressed on dermal blood vessels and epidermal appendages, but not in interfollicular epidermis.
  • Marked induction was detected within benign and malignant tumors of various origins including viral warts, basal cell carcinomas, squamous cell carcinomas, metastatic melanomas, and cutaneous T cell lymphomas.
  • Surprisingly, gp130 was also induced in inflammatory skin diseases including psoriasis and allergic contact dermatitis.
  • Halting proliferation of transformed keratinocytes through cytostatic drugs or increasing the Ca2+ concentration in the medium resulted in increased gp130 expression.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma, Squamous Cell / metabolism. Membrane Glycoproteins / metabolism. Neural Cell Adhesion Molecules / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Antigens, CD146. Blotting, Western. Carcinoma, Basal Cell / metabolism. Cell Line, Transformed. Cells, Cultured. Dermatitis, Allergic Contact / metabolism. Dermis / metabolism. Epidermis / metabolism. Glycosylation. Humans. Immunoprecipitation. Keratinocytes / cytology. Keratinocytes / metabolism. Lymphoma, T-Cell / metabolism. N-Acetylneuraminic Acid / metabolism. Peptide Mapping. Psoriasis / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098047.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD146; 0 / MCAM protein, human; 0 / Membrane Glycoproteins; 0 / Neural Cell Adhesion Molecules; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


80. Ackerman AB, Gottlieb GJ: Fibroepithelial tumor of pinkus is trichoblastic (Basal-cell) carcinoma. Am J Dermatopathol; 2005 Apr;27(2):155-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibroepithelial tumor of pinkus is trichoblastic (Basal-cell) carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Hair Diseases / pathology. Hair Follicle / pathology. Neoplasms, Fibroepithelial / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sex Factors

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798443.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


81. Filho LL, de Oliveira de Avelar Alchorne A, Pereira GC, Lopes LR, de Carvalho TC: Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication. Int J Dermatol; 2008 Jun;47(6):610-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most frequent non-melanoma skin cancer.
  • Curettage and electrosurgery is probably the method most commonly used by dermatologists for the treatment of small and low risk BCCs.
  • METHODS: 20 primary BCC outpatients were studied at the Dermatology Service of Getúlio Vargas Hospital in the city of Teresina--State of Piauí--Brazil, with lesions of up to 1 cm in diameter on the face, and up to 1.5 cm elsewhere, and with no clinical signs of sclerosing and micronodular forms.
  • After two curettage and electrofulguration cycles, an incision around the resultant ulcer was made 2 mm beyond the visible bloody borders and in the base to the middle of subcutaneous fat.
  • RESULTS: There was evidence of persistent BCC in 5 of the 20 sites treated (25%): four (20%) in one quadrant and one (5%) in all four quadrants.
  • 70-100% of tumor cells expressed Ber-EP4 in all 20 BCCs.
  • CONCLUSIONS: The persistence of tumoral residues after 2 curettage and electrofulguration cycles for basal cell carcinoma was found in 5 sites treated (25%).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Curettage. Electrosurgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm, Residual. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477158.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


82. de Almeida OM, Gemperli R: Reconstruction of a postauricular defect using a preauricular flap. Dermatol Surg; 2010 Jul;36(7):1191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Ear Auricle. Ear Neoplasms / surgery. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653732.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Megehee JA, Hosler JP, Lundrigan MD: Evidence for a cytochrome bcc-aa3 interaction in the respiratory chain of Mycobacterium smegmatis. Microbiology; 2006 Mar;152(Pt 3):823-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a cytochrome bcc-aa3 interaction in the respiratory chain of Mycobacterium smegmatis.
  • Spectroscopic analysis of membranes isolated from Mycobacterium smegmatis, along with analysis of its genome, indicates that the cytochrome c branch of its respiratory pathway consists of a modified bc1 complex that contains two cytochromes c in its c1 subunit, similar to other acid-fast bacteria, and an aa3-type cytochrome c oxidase.
  • A functional association of the cytochrome bcc and aa3 complexes was indicated by the findings that levels of detergent sufficient to completely disrupt isolated membranes failed to inhibit quinol-driven O2 reduction, but known inhibitors of the bc1 complex did inhibit quinol-driven O2 reduction.
  • However, high concentrations of monovalent salts had no effect on O2 reduction, suggesting that ionic interactions between extramembrane domains do not play the major role in stabilizing the bcc-aa3 interaction.
  • The results indicate that hydrophobic interactions are the primary forces maintaining the bcc-aa3 interaction, but ionic interactions may assist in aligning the two complexes for efficient electron transfer.
  • [MeSH-major] Electron Transport Complex III / metabolism. Electron Transport Complex IV / metabolism. Mycobacterium smegmatis / physiology
  • [MeSH-minor] Cell Membrane / enzymology. Electron Transport. Hydrophobic and Hydrophilic Interactions. Oxygen Consumption

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514162.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM56824
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.10.2.2 / Electron Transport Complex III; EC 1.9.3.1 / Electron Transport Complex IV
  •  go-up   go-down


84. Ko CJ, Barr RJ, Subtil A, McNiff JM: Acantholytic dyskeratotic acanthoma: a variant of a benign keratosis. J Cutan Pathol; 2008 Mar;35(3):298-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We screened cases at our institution over a 6-month period and found 28 such lesions.
  • Lesions were most often found on the trunk as a solitary papule, for which the clinical diagnosis was often basal cell carcinoma.
  • [MeSH-major] Acantholysis / pathology. Acanthoma / pathology. Keratosis / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Acanthoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251744.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


85. Gunay Y, Erkan M, Gurbuzer B, Karayazgan B: Facilitation of facial prosthesis placement with tattoo markers: a clinical report. J Prosthet Dent; 2007 May;97(5):256-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This clinical report describes a method of using tattoo marks as references to repeatably align the facial prosthesis of a patient with a skin flap reconstruction.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Ear, External. Prostheses and Implants. Prosthesis Design / methods. Skin Neoplasms / surgery. Tattooing

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17547942.001).
  • [ISSN] 0022-3913
  • [Journal-full-title] The Journal of prosthetic dentistry
  • [ISO-abbreviation] J Prosthet Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Jahagirdar SS, Thakre TP, Kale SM, Kulkarni H, Mamtani M: A clinicopathological study of eyelid malignancies from central India. Indian J Ophthalmol; 2007 Mar-Apr;55(2):109-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment depends on the invasiveness of the cancer which in turn depends on the type of malignancy.
  • MATERIALS AND METHODS: We report a series of 27 cases of eyelid malignancies.
  • In the same case series, we also include a case of malignant hemangiopericytoma which is an extremely rare form of eyelid malignancy worldwide.
  • RESULTS: We observed that sebaceous cell carcinoma (approximately 37%) was almost as prevalent as basal cell carcinoma (approximately 44%) in the study subjects and had an earlier age of occurrence and a more rapid clinical course.
  • CONCLUSIONS: Sebaceous cell carcinoma of the eyelid is almost as common as basal cell carcinoma in a large tertiary care centre in central India.
  • [MeSH-minor] Adenocarcinoma, Sebaceous / epidemiology. Adenocarcinoma, Sebaceous / pathology. Adenocarcinoma, Sebaceous / surgery. Biopsy, Fine-Needle. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Diagnosis, Differential. Female. Hemangiopericytoma / epidemiology. Hemangiopericytoma / pathology. Hemangiopericytoma / surgery. Humans. India / epidemiology. Male. Middle Aged. Neoplasm Staging. Ophthalmologic Surgical Procedures / methods. Prevalence. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322599.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


87. Zarineh A, Kozovska ME, Brown WG, Elder DE, Rabkin MS: Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature. J Cutan Pathol; 2008 Oct;35 Suppl 1:83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature.
  • Unlike a recently reported case of SMH combined with a melanocytic nevus and basal cell carcinoma, the current lesion did not occur in association with a Becker's nevus.
  • [MeSH-minor] Actins / metabolism. Antigens, Neoplasm / metabolism. Calmodulin-Binding Proteins / metabolism. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544054.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Calmodulin-Binding Proteins; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


88. Kolár Z, Geierová M, Bouchal J, Pazdera J, Zboril V, Tvrdý P: Immunohistochemical analysis of the biological potential of odontogenic keratocysts. J Oral Pathol Med; 2006 Feb;35(2):75-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Nevoid basal cell carcinoma syndrome (NBCCS) keratocysts were characterized by higher expression of Bcl-2, p27Kip1 and c-erbB-2 as well as by lower proliferative activity measured by Ki-67 in basal cell epithelium and by a lower inflammatory response in comparison with sporadic keratocysts.
  • Dentigerous, radicular and non-specified odontogenic cysts differed from both NBCCS and sporadic keratocysts in a wide spectrum of apoptosis and/or cell cycle-related protein expressions, higher proliferation in the basal cell layer, and vice versa, lower proliferation in the suprabasal cell layer.
  • [MeSH-minor] Apoptosis / physiology. Apoptosis Regulatory Proteins / analysis. Basal Cell Nevus Syndrome / metabolism. Basal Cell Nevus Syndrome / pathology. Biology. Biomarkers / analysis. Cell Cycle Proteins / analysis. Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p27 / analysis. Dentigerous Cyst / chemistry. Dentigerous Cyst / pathology. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Humans. Immunohistochemistry. Immunophenotyping. Ki-67 Antigen / analysis. Prognosis. Protein Kinase Inhibitors / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Radicular Cyst / chemistry. Radicular Cyst / pathology. Receptor, ErbB-2 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430736.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


89. Kepron C, Reis P, Bharadwaj R, Shaw J, Kamel-Reid S, Ghazarian D: Identification of genomic predictors of non-melanoma skin cancer in solid organ transplant recipients. Eur J Dermatol; 2009 May-Jun;19(3):278-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genomic predictors of non-melanoma skin cancer in solid organ transplant recipients.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Expression. Organ Transplantation. Skin Neoplasms / genetics
  • [MeSH-minor] CCAAT-Enhancer-Binding Proteins / genetics. Case-Control Studies. Galanin / genetics. Humans. Matrix Metalloproteinase 3 / genetics. Predictive Value of Tests. Steroid Isomerases / genetics

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307168.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / GAL protein, human; 88813-36-9 / Galanin; EC 3.4.24.17 / MMP3 protein, human; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 5.3.3.- / Steroid Isomerases; EC 5.3.3.5 / EBP protein, human
  •  go-up   go-down


90. Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B, Ritter E, Gnjatic S, Kristiansen G, Moch H, Knuth A, Dummer R, van den Broek M: Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res; 2010 Jul 15;16(14):3562-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas.
  • PURPOSE: Nonmelanoma skin cancer is the most common cancer and comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • To find an explanation for the selective immunosurveillance of SCC, we investigated the expression of cancer-testis (CT) antigens and MHC class I (MHC-I) and the infiltration by immune cells in BCC and SCC.
  • EXPERIMENTAL DESIGN: We determined the expression of 23 different CT-antigens in 63 BCC and 40 SCC biopsies of immunocompetent and in 20 biopsies of immunosuppressed SCC patients by reverse transcription-PCR and immunohistochemistry.
  • MHC-I expression and CD8(+) T-cell infiltration were analyzed by immunohistochemistry in BCC and SCC of immunocompetent and immunosuppressed patients and in imiquimod-treated BCC patients.
  • RESULTS: We found expression of at least one CT-antigen in 81% of BCC and in 40% of SCC.
  • Most SCC, but not BCC, expressed MHC-I and were infiltrated with CD8(+) cells.
  • Imiquimod-treated BCC expressed MHC-I and were infiltrated by CD8(+) T cells.
  • CONCLUSIONS: We propose that immunosurveillance controls SCC, but not BCC, because the latter lacks MHC-I.
  • This fits with the increased incidence of SCC in immunosuppressed individuals and may explain the relatively low prevalence of CT-antigen expression in SCC as a result of CD8(+) T-cell-driven immunoediting.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Carcinoma, Basal Cell / immunology. Carcinoma, Squamous Cell / immunology. Histocompatibility Antigens Class I / biosynthesis. Monitoring, Immunologic. Skin Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20519358.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


91. Chren MM: Determining the value of surgical therapies for basal cell carcinoma. Arch Dermatol; 2006 Feb;142(2):231-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the value of surgical therapies for basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Dermatol. 2006 Feb;142(2):187-94 [16490846.001]
  • (PMID = 16490852.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Editorial
  • [Publication-country] United States
  •  go-up   go-down


92. Zinkernagel MS, Catalano E, Ammann-Rauch D: Free tarsal graft combined with skin transposition flap for full-thickness lower eyelid reconstruction. Ophthal Plast Reconstr Surg; 2007 May-Jun;23(3):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free tarsal graft combined with skin transposition flap for full-thickness lower eyelid reconstruction.
  • We present the surgical outcome in a series of 4 patients with large full-thickness eyelid defects after basal cell carcinoma excision.
  • The patients underwent reconstructive eyelid surgery using autogenous free tarsal grafts combined with a skin transposition flap from the upper eyelid.
  • In all 4 cases, posterior lamellae were reconstructed using a free tarsal graft, and the outer lamella was developed with a transposition skin flap from the upper eyelid.
  • The skin flap provided adequate vascular support in all cases.
  • Autogenous tarsus as a free graft proves to be a simple procedure for posterior lamella substitution in lower eyelid surgery, especially in combination with a skin transposition flap from the upper eyelid.
  • [MeSH-major] Eyelids / transplantation. Ophthalmologic Surgical Procedures. Reconstructive Surgical Procedures. Skin Transplantation / methods. Surgical Flaps
  • [MeSH-minor] Adult. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / pathology. Eyelid Neoplasms / surgery. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519664.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Yang SH, Andl T, Grachtchouk V, Wang A, Liu J, Syu LJ, Ferris J, Wang TS, Glick AB, Millar SE, Dlugosz AA: Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. Nat Genet; 2008 Sep;40(9):1130-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling.
  • Constitutive Hedgehog (Hh) signaling underlies several human tumors, including basal cell carcinoma (BCC) and basaloid follicular hamartoma in skin.
  • Intriguingly, superficial BCCs arise as de novo epithelial buds resembling embryonic hair germs, collections of epidermal cells whose development is regulated by canonical Wnt/beta-catenin signaling.
  • Similar to embryonic hair germs, human BCC buds showed increased levels of cytoplasmic and nuclear beta-catenin and expressed early hair follicle lineage markers.
  • We also detected canonical Wnt/ beta-catenin signaling in epithelial buds and hamartomas from mice expressing an oncogene, M2SMO, leading to constitutive Hh signaling in skin.
  • Our findings uncover a hitherto unknown requirement for ligand-driven, canonical Wnt/ beta-catenin signaling for Hh pathway-driven tumorigenesis, identify a new pharmacological target for these neoplasms and establish the molecular basis for the well-known similarity between early superficial BCCs and embryonic hair germs.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] Dev Cell. 2002 May;2(5):643-53 [12015971.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4489-98 [17297467.001]
  • [Cites] PLoS One. 2007;2(11):e1155 [17982507.001]
  • [Cites] J Am Acad Dermatol. 2008 Jan;58(1):158-67 [18158927.001]
  • [Cites] J Cell Biol. 2008 Jan 28;180(2):273-84 [18209104.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Arch Derm Syphilol. 1948 Apr;57(4):679-724 [18886278.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):181-92 [15978322.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Arch Dermatol. 2005 Jan;141(1):60-7 [15655143.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2724-9 [15545630.001]
  • [Cites] Dev Biol. 1999 Jan 1;205(1):1-9 [9882493.001]
  • [Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]
  • [Cites] Curr Biol. 1998 Sep 24;8(19):1058-68 [9768360.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Development. 2004 Oct;131(19):4819-29 [15342465.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):157-64 [15270885.001]
  • [Cites] Development. 2004 Apr;131(8):1787-99 [15084463.001]
  • [Cites] Development. 2003 Nov;130(21):5241-55 [12954714.001]
  • [Cites] Br J Dermatol. 2003 May;148(5):964-70 [12786827.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2741-51 [12773389.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):130-7 [12652194.001]
  • [Cites] Nature. 2002 Jun 6;417(6889):664-7 [12050670.001]
  • [Cites] Nature. 2007 May 17;447(7142):316-20 [17507982.001]
  • [Cites] Br J Dermatol. 2001 Nov;145(5):771-7 [11736900.001]
  • [Cites] Curr Biol. 2001 May 15;11(10):769-73 [11378387.001]
  • [Cites] Cell. 2001 May 18;105(4):533-45 [11371349.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [CommentIn] Nat Genet. 2008 Sep;40(9):1040-1 [19165916.001]
  • (PMID = 19165927.001).
  • [ISSN] 1061-4036
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01-AR47709; United States / NIAMS NIH HHS / AR / AR045973-09; United States / NIDCR NIH HHS / DE / R01 DE015342-01A2; United States / NCI NIH HHS / CA / R01 CA087837-01; United States / NCI NIH HHS / CA / CA087837-09; United States / NIAMS NIH HHS / AR / R01 AR047709-01; United States / NIDCR NIH HHS / DE / DE015342-01A2; United States / NCI NIH HHS / CA / P30-CA46592; United States / NIGMS NIH HHS / GM / GM007863-19; United States / NCI NIH HHS / CA / P30 CA046592; United States / NICHD NIH HHS / HD / T32 HD007505-02; United States / NICHD NIH HHS / HD / HD007505-02; United States / NCI NIH HHS / CA / R01 CA087837-09; United States / NIGMS NIH HHS / GM / T32 GM007863-19; United States / NIAMS NIH HHS / AR / R01 AR045973-09; United States / NCI NIH HHS / CA / P30 CA046592-109015; United States / NIGMS NIH HHS / GM / T32-GM07863; United States / NIAMS NIH HHS / AR / R01 AR047709; United States / NICHD NIH HHS / HD / T32 HD007505; United States / NIAMS NIH HHS / AR / R01-AR45973; United States / NIGMS NIH HHS / GM / T32 GM007863; United States / NIDCR NIH HHS / DE / R01-DE015342; United States / NIAMS NIH HHS / AR / AR047709-01; United States / NCI NIH HHS / CA / CA046592-109015; United States / NIAMS NIH HHS / AR / R01 AR045973; United States / NIAMS NIH HHS / AR / AR045973-01A1; United States / NCI NIH HHS / CA / R01 CA087837; United States / NICHD NIH HHS / HD / T32-HD007505; United States / NIAMS NIH HHS / AR / R01 AR045973-01A1; United States / NCI NIH HHS / CA / R01-CA87837; United States / NIDCR NIH HHS / DE / R01 DE015342
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Oncogene Proteins; 0 / Wnt Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS91012; NLM/ PMC2688690
  •  go-up   go-down


94. Smeets R, Kolk A, Gerressen M, Driemel O, Maciejewski O, Hermanns-Sachweh B, Riediger D, Stein JM: A new biphasic osteoinductive calcium composite material with a negative Zeta potential for bone augmentation. Head Face Med; 2009;5:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to analyze the osteogenic potential of a biphasic calcium composite material (BCC) with a negative surface charge for maxillary sinus floor augmentation.
  • In a 61 year old patient, the BCC material was used in a bilateral sinus floor augmentation procedure.
  • The BCC was biocompatible and replaced by new mineralized bone after being resorbed completely.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Implants. 1999 Nov-Dec;14(6):869-78 [10612926.001]
  • [Cites] Acta Biomater. 2008 Mar;4(2):397-402 [18054299.001]
  • [Cites] J Biomed Mater Res. 2001 Jun 5;55(3):387-95 [11255192.001]
  • [Cites] Clin Oral Implants Res. 2001 Aug;12(4):379-84 [11488868.001]
  • [Cites] J Periodontol. 2001 Jul;72(7):911-20 [11495140.001]
  • [Cites] J Biomed Mater Res. 2001 Dec 5;57(3):366-73 [11523031.001]
  • [Cites] Int J Oral Maxillofac Implants. 2001 Sep-Oct;16(5):681-92 [11669251.001]
  • [Cites] J Dent Res. 2001 Oct;80(10):1925-9 [11706953.001]
  • [Cites] Eur Spine J. 2001 Oct;10 Suppl 2:S96-101 [11716023.001]
  • [Cites] Int J Periodontics Restorative Dent. 2002 Oct;22(5):503-8 [12449310.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2004 Feb 15;68(2):199-208 [14737769.001]
  • [Cites] J Biomed Mater Res A. 2004 Sep 1;70(3):436-41 [15293317.001]
  • [Cites] J Oral Surg. 1980 Aug;38(8):613-6 [6993637.001]
  • [Cites] Dent Clin North Am. 1986 Apr;30(2):207-29 [3516738.001]
  • [Cites] Clin Orthop Relat Res. 1988 Jul;(232):127-38 [2838207.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Mar;47(3):238-42 [2646403.001]
  • [Cites] Int J Oral Maxillofac Implants. 1988 Fall;3(3):209-14 [3074053.001]
  • [Cites] Int J Oral Maxillofac Implants. 1993;8(5):523-8 [8112791.001]
  • [Cites] Calcif Tissue Int. 1994 Aug;55(2):151-8 [7953981.001]
  • [Cites] J Biomed Mater Res. 1997 Mar 15;34(4):507-17 [9054534.001]
  • [Cites] Biochem Cell Biol. 1997;75(1):81-7 [9192077.001]
  • [Cites] Clin Oral Implants Res. 1998 Feb;9(1):59-64 [9590946.001]
  • [Cites] Clin Oral Implants Res. 1998 Apr;9(2):107-16 [9663038.001]
  • [Cites] Int J Periodontics Restorative Dent. 1998 Jun;18(3):227-39 [9728105.001]
  • [Cites] Int J Oral Maxillofac Implants. 1998 Nov-Dec;13(6):866-73 [9857600.001]
  • [Cites] Orthop Clin North Am. 1999 Oct;30(4):615-23 [10471766.001]
  • [Cites] Clin Oral Implants Res. 2004 Dec;15(6):724-32 [15533134.001]
  • [Cites] Biomaterials. 2005 Jun;26(17):3395-404 [15621228.001]
  • [Cites] Biomaterials. 2005 Dec;26(34):6818-26 [15955555.001]
  • [Cites] Int J Periodontics Restorative Dent. 2006 Feb;26(1):79-85 [16515099.001]
  • [Cites] Int J Periodontics Restorative Dent. 2006 Apr;26(2):113-25 [16642900.001]
  • [Cites] Implant Dent. 2006 Jun;15(2):197-207 [16766904.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Aug;35(8):708-13 [16690249.001]
  • [Cites] Int J Periodontics Restorative Dent. 2006 Oct;26(5):471-81 [17073357.001]
  • [Cites] J Mater Sci Mater Med. 2008 Feb;19(2):667-75 [17619955.001]
  • [Cites] Clin Oral Implants Res. 2000 Jun;11(3):217-29 [11168213.001]
  • (PMID = 19523239.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Substitutes; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2706807
  •  go-up   go-down


95. Dong X, Reddy GB: Soil bacterial communities in constructed wetlands treated with swine wastewater using PCR-DGGE technique. Bioresour Technol; 2010 Feb;101(4):1175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that the bacterial colony forming units (CFU) and the average concentrations of total nitrogen, NH(4)(+), total phosphorous (TP) and PO(4)(3-) from the influent to the effluent decreased.
  • The NH(4)(+) and the PO(4)(3-) concentrations showed the most dramatic changes, with decreases of 39.97% and 16.92%, respectively.
  • Bacterium species distributions strongly correlated with the concentrations of TP, NH(4)(+) and the PO(4)(3-).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822421.001).
  • [ISSN] 1873-2976
  • [Journal-full-title] Bioresource technology
  • [ISO-abbreviation] Bioresour. Technol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


96. Scheithauer BK, Wos-Oxley ML, Ferslev B, Jablonowski H, Pieper DH: Characterization of the complex bacterial communities colonizing biliary stents reveals a host-dependent diversity. ISME J; 2009 Jul;3(7):797-807
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the complex bacterial communities colonizing biliary stents reveals a host-dependent diversity.
  • This study provides a comprehensive survey of the spatial and temporal bacterial composition of biliary stent biofilms.
  • The bacterial diversity, distribution and dynamics of 59 biliary and 4 pancreatic stent communities from 40 patients being treated at two different hospitals, which implant stents either simultaneously or consecutively, were characterized by single-strand conformation polymorphism (SSCP) analysis.
  • Co-colonization of Veillonella sp., Streptococcus anginosus and organisms closely related to Fusobacterium nucleatum revealed a potentially important attachment and survival strategy that has yet to be reported in biliary stents.
  • This work reveals a more complete survey of the identities of bacterial species that form biofilms in biliary stents, their co-colonization patterns and the natural variation in species composition between different patients, hospitals and locations along the stent.

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360025.001).
  • [ISSN] 1751-7370
  • [Journal-full-title] The ISME journal
  • [ISO-abbreviation] ISME J
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU704129/ EU704130/ EU704131/ EU704132/ EU704133/ EU704134/ EU704135/ EU704136/ EU704137/ EU704138/ EU704139/ EU704140/ EU704141/ EU704142/ EU704143/ EU704144/ EU704145/ EU704146/ EU704147/ EU704148/ EU704149/ EU704150/ EU704151/ EU704152/ EU704153/ EU704154/ EU704155/ EU704156/ EU704157/ EU704158/ EU704159/ EU704160/ EU704161/ EU704162/ EU704163/ EU704164/ EU704165/ EU704166/ EU704167/ EU704168/ EU704169/ EU704170/ EU704171/ EU704172/ EU704173/ EU704174/ EU704175/ EU704176/ EU704177/ EU704178/ EU704179/ EU704180/ EU704181/ EU704182/ EU704183/ EU704184/ EU704185/ EU704186/ EU704187/ EU704188/ EU704189/ EU704190/ EU704191/ EU704192/ EU704193/ EU704194/ EU704195/ EU704196/ EU704197/ EU704198/ EU704199/ EU704200/ EU704201/ EU704202/ EU704203/ EU704204/ EU704205/ EU704206/ EU704207/ EU704208/ EU704209/ EU704210/ EU704211/ EU704212/ EU704213/ EU704214/ EU704215/ EU704216/ EU704217/ EU704218/ EU704219/ EU704220/ EU704221/ EU704222/ EU704223/ EU704224/ EU704225/ EU704226/ EU704227/ EU704228/ EU704229/ EU704230/ EU704231/ EU704232/ EU704233/ EU704234/ EU704235/ EU704236/ EU704237/ EU704238/ EU704239/ EU704240/ EU704241/ EU704242/ EU704243/ EU704244/ EU704245/ EU704246/ EU704247/ EU704248/ EU704249/ EU704250/ EU915501/ EU915502/ EU915503/ EU915504
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


97. Wang Z, Xu Y, Tang J, Ma H, Qin J, Lu C, Wang X, Hu Z, Wang X, Shen H: A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women. Breast Cancer Res Treat; 2009 Nov;118(1):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women.
  • RecQ helicases play a central role in maintaining genome stability and may interact with some important cancer-related proteins such as BRCA1.
  • Mutations of the human RecQ helicase genes WRN and BLM lead to rare autosomal recessive disorders, Werner and Bloom syndromes, which are associated with premature aging and cancer predisposition, including breast cancer.
  • In this case-control study of 1,004 breast cancer cases and 1,008 controls, we tested the hypothesis that non-conservative amino acid exchanges in WRN (leu1074Phe), BLM (Met298Thr) and BRCA1 (Pro871Leu) are independently or jointly associated with the risk of breast cancer in Chinese women.
  • We found that the variant genotype of WRN Leu1074Phe was associated with a 1.36-fold significantly increased risk of breast cancer (OR = 1.36, 95% CI = 1.06-1.74).
  • Subjects carrying Phe/Phe genotype and with earlier age at menarche had 3.58-fold increased risk of breast cancer (OR = 3.58, 95% CI = 2.54-5.05).
  • These findings indicate that WRN leu1074Phe variant may contribute to the susceptibility of breast cancer in Chinese women.
  • [MeSH-major] Breast Neoplasms / genetics. Exodeoxyribonucleases / genetics. Genes, Neoplasm. Menarche / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. RecQ Helicases / genetics. Werner Syndrome / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Substitution. Case-Control Studies. China / epidemiology. Female. Genes, BRCA1. Genetic Predisposition to Disease. Genotype. Humans. Menopause. Middle Aged. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Risk

  • Genetic Alliance. consumer health - Werner's syndrome.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205873.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.1.- / Exodeoxyribonucleases; EC 3.6.1.- / Bloom syndrome protein; EC 3.6.1.- / WRN protein, human; EC 3.6.4.12 / RecQ Helicases
  •  go-up   go-down


98. Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS: Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer; 2009 Feb 24;100(4):563-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women.
  • As the epidemiological pattern of breast cancer in modernising Asian countries differs greatly from that in Western countries, it is worthwhile to investigate the long-term prognoses of unilateral and bilateral breast cancer in these nations.
  • A retrospective cohort study composed of 1907 Taiwanese women was conducted to follow 1863 unilateral and 44 bilateral cases of breast cancer.
  • Time-dependent Cox regression was used to assess the risk of breast cancer death by considering the time course of unilateral and bilateral tumour development.
  • The 15-year survival rates were 68.37, 62.63, and 26.42% for unilateral, synchronous bilateral, and metachronous bilateral breast cancer, respectively.
  • After adjusting for significant prognostic factors, the risk of death for overall bilateral breast cancer was 2.50-fold greater (95% CI, 1.43-4.37) compared to unilateral breast cancer.
  • The corresponding figures were 1.12-fold (95% CI, 0.42-3.02) and 6.11-fold (95% CI, 3.14-11.89) for synchronous and metachronous bilateral breast cancer, respectively.
  • Taiwanese women, who are frequently diagnosed with breast cancer before 50 years of age, showed poorer survival for metachronous bilateral than for synchronous bilateral or unilateral breast cancer.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 May 27;355(9218):1869-74 [10866443.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2774-80 [19027287.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1117-24 [11571945.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):901-6 [14712495.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):27-30; discussion 31 [14718270.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3002-11 [6498774.001]
  • [Cites] Aust N Z J Surg. 1989 Jan;59(1):35-7 [2913992.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1819-27 [8230262.001]
  • [Cites] Cancer. 1993 Dec 15;72(12):3629-35 [8252478.001]
  • [Cites] Am J Epidemiol. 1995 Dec 15;142(12):1255-64 [7503045.001]
  • [Cites] N Engl J Med. 1996 Jan 18;334(3):143-9 [8531968.001]
  • [Cites] Int J Epidemiol. 1996 Feb;25(1):40-5 [8666502.001]
  • [Cites] Am J Clin Oncol. 1997 Dec;20(6):541-5 [9391536.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1103-9 [10339665.001]
  • [Cites] Fam Cancer. 2004;3(3-4):249-57 [15516849.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):302-6 [15386413.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50 [15668501.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1986-90 [16103449.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):221-8 [16544057.001]
  • [Cites] BMC Cancer. 2006;6:261 [17078893.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2360-8 [17515570.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1017-20 [17471561.001]
  • [Cites] N Engl J Med. 2007 Jul 12;357(2):115-23 [17625123.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1437-42 [17627009.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4210-6 [17878475.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3324-30 [18612148.001]
  • [Cites] Cancer Detect Prev. 2008;32(2):156-61 [18632223.001]
  • [Cites] Cancer. 2001 May 15;91(10):1845-53 [11346865.001]
  • (PMID = 19190627.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653740
  •  go-up   go-down


99. Melchor L, Honrado E, Huang J, Alvarez S, Naylor TL, García MJ, Osorio A, Blesa D, Stratton MR, Weber BL, Cigudosa JC, Rahman N, Nathanson KL, Benítez J: Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res; 2007 Dec 15;13(24):7305-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
  • PURPOSE: Familial breast cancer represents 5% to 10% of all breast tumors.
  • Mutations in the two known major breast cancer susceptibility genes, BRCA1 and BRCA2, account for a minority of familial breast cancer, whereas families without mutations in these genes (BRCAX group) account for 70% of familial breast cancer cases.
  • EXPERIMENTAL DESIGN: To better characterize and define the genomic differences between the three classes of familial tumors and sporadic malignancies, we have analyzed 19 BRCA1, 24 BRCA2, and 31 BRCAX samples from familial breast cancer patients and 19 sporadic breast tumors using a 1-Mb resolution bacterial artificial chromosome array-based comparative genomic hybridization.
  • There were common genomic alterations present in all breast cancer groups, such as gains of 1q and 16p or losses of 8ptel-p12 and 16q.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Genes, BRCA1. Genes, BRCA2. Genomic Instability. Receptors, Estrogen / metabolism
  • [MeSH-minor] Chromosomes, Artificial, Bacterial. Female. Genetic Predisposition to Disease. Humans. Mutation. Nucleic Acid Hybridization


100. Homaei-Shandiz F, Ghavam-Nassiri MR, Sharifi N, Homaei-Shandiz AH, Taghizadeh-Kermani A, Torshizi SA, Ghafarzadegan K: Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer. Saudi Med J; 2006 Dec;27(12):1810-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
  • OBJECTIVE: The human epidermal growth factor receptor-2 (HER-2)/neu is a proto-oncogene that is amplified in 10-30% of breast cancers.
  • We studied the relationship between its amplification and different histological gradings of breast cancer.
  • METHODS: We studied 196 patients diagnosed with breast cancer in 2005 at the Omid and Ghaem Training Hospital, Mashhad Medical University, Iran.
  • RESULTS: Sixty-seven (34.2%) cases were HER-2/neu positive and 129 (65.8%) cases were HER-2/neu negative.
  • Overexpression of HER-2/neu was significantly higher in breast cancer patients <30 years (50% versus 33.3%, p=0.034).
  • Twelve (17.5%) of HER-2/neu positive cases were metastatic and only 4 (3.1%) of HER-2/neu negative cases had metastasis (p=0.051).
  • CONCLUSION: HER-2/neu gene amplification or its overexpression is detected in approximately 34.2% of breast cancer cases.
  • Patients with HER-2/neu positive breast cancer have higher stage and grade diseases.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Gene Amplification. Gene Expression Regulation, Neoplastic / genetics. Receptor, ErbB-2 / genetics






Advertisement